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Letters to the Editor
J Med Genet 2000;37:210–212
No evidence of germline PTEN
mutations in familial prostate cancer
EDITOR—Prostate cancer is the second most common
cause of male cancer mortality in the UK.1 Current indica-
tions are that like many common cancers, prostate cancer
has an inherited component.2 Segregation analysis has led
to the proposed model of at least one highly penetrant,
dominant gene (with an estimated 88% penetrance for
prostate cancer by the age of 85 in the highly susceptible
population). Such a gene or genes would account for an
estimated 43% of cases diagnosed at less than 55 years.2
One prostate cancer susceptibility locus (HPC1) has been
reported on 1q24-253 and confirmed by Cooney et al4 and
Gronberg et al.5 Latest estimates suggest that this locus
would only account for 4% of families overall in the UK
(upper 95% confidence interval (CI) limit of 31%).6
Another locus has been reported on 1q42.2-43 after a
genome wide search of 47 French and German families.7
This locus is estimated to explain 50% of these families and
appears to be distinct from the HPC1 locus as the two are
estimated to be 60 cM apart. Confirmatory studies of this
second locus have not yet been reported. A third locus has
been reported. This locus, situated on the X chromosome, is
estimated to explain approximately 16% of the families
studied (including the families which were first typed to map
the 1q24 locus).8 The heterogeneity lod score for linkage to
this locus is 3.85 with the strongest evidence being a locus in
proximity to the markers DXS297 and DXS1200.
While linkage studies have not identified chromosome
10 as the site of a predisposing gene, the long arm of chro-
mosome 10 is the fourth commonest region showing loss of
heterozygosity (LOH) in sporadic prostate cancers after
7q, 8p, and 16q.9 Deletion mapping studies have identified
10q23 to be the minimal region of loss.10–12 One candidate
gene which maps adjacent to this region, MXI1, has been
assessed for a role in familial prostate cancer susceptibility
but no germline mutations were identified.13 PTEN/
MMAC1 (Phosphatase and Tensin homologue deleted on
chromosome Ten/Mutated in Multiple Advanced Cancers
1), a tumour suppressor gene, has recently been identified
at 10q23 through mapping of homozygous deletions in
tumour cell lines.14–16 Li et al14 15 and Steck et al16 found
PTEN mutations in four out of four and one out of three
prostate cancer cell lines respectively, suggesting a role in
prostate carcinogenesis.15 16 Cairns et al17 found LOH at
10q in 23 of 80 prostate tumours. Sequencing identified a
mutation in PTEN in 10 of these 23 tumours (43%).17
More recently, Wang et al18 found that of 60 prostate
adenocarcinomas, 10-15% of primary stage B prostate
carcinomas had PTEN inactivation by homozygous
deletion. A number of studies have examined the frequency
of somatic mutations in this gene. For instance, somatic
mutations have been found in glioblastomas, melanomas,
and breast and prostate carcinomas.15 16 Germline muta-
tions in PTEN have been shown to be the cause of Cowden
disease,19 20 while PTEN deficient mice (PTEN +/-) show
hyperplastic and dysplastic changes in the prostate and
indeed develop prostate cancer.21 22
We hypothesised that germline PTEN mutations could
be important in familial prostate cancer for the following
three reasons: somatic mutations have been found in PTEN
in prostate tumours; germline mutations in Cowden
disease produce a phenotype (although with no evidence of
an associated susceptibility to prostate cancer); and PTEN
deficient mice exhibit prostate abnormalities. We have
therefore screened the Cancer Research Campaign/British
Prostate Group (CRC/BPG) UK Familial Prostate Cancer
Study samples for evidence of PTEN mutations.
The CRC/BPG UK Familial Prostate Cancer Study has
collected lymphocyte DNA from 188 subjects from 50
prostate cancer families. These families were chosen
because each contained three or more cases of prostate
cancer at any age or related sib pairs where at least one man
was less than 67 (original criterion was 65) years old at
diagnosis. In fact, the majority of the clusters consist of
aVected sib pairs, with DNA often only available from
cases. Twenty eight of the families had two aVected males,
10 had three aVected, nine had four aVected, and three had
five aVected; the average age of onset was 66.9 years. Sam-
ple family pedigrees and DNA extraction protocols are
described in Edwards et al.13 These families were previously
analysed for linkage to HPC1 and showed no evidence for
linkage.6 DNA extracted from a known Cowden disease
patient was used as a positive control for mutational analy-
sis. The study was approved by the Royal Marsden NHS
Trust Local Research Ethics Committee.
Linkage analysis was performed after genotyping using
three polymorphic DNA markers flanking PTEN
(D10S541, D10S1765, and D10S2491). Lod scores for
linkage to PTEN were calculated under the assumption
that prostate cancer was caused by an autosomal dominant
gene with Carter’s estimate of penetrance2 using the
GENEHUNTER software23 and assuming the marker
order of D10S1765/D10S2491 - 20.5 kb - PTEN - 0.2 cM
- D10S541. Under this model of inheritance, there is an
assumed lifetime penetrance (to 85 years of age) of 88% for
prostate cancer in the highly susceptible population and
with 0.6% of the general population carrying such a
predisposition. The risk to age 85 in the non-susceptible
male UK population was assumed to be 6.5%. Linkage
analysis was performed under a model of homogeneity
with PTEN being the only high penetrance predisposition
gene for prostate cancer and also under a model of
heterogeneity in which other high penetrance predisposi-
tions were assumed. For D10S1765 and D10S541, the
allele frequencies were estimated from the family data,
while for D10S2491 the alleles were assumed to be equally
frequent as limited typing precluded estimation (at the
time this was a new marker with no published allele
frequencies). Non-parametric analysis of linkage was also
performed using the NPL statistic of GENEHUNTER.23
Pairwise and multipoint linkage analysis showed no
evidence of linkage to the PTEN region. Indeed, under
homogeneity and tight linkage there was strong evidence
against the hypothesis of a gene in the region of PTEN,
which approached the conventional limit for exclusion map-
ping; the multipoint lod score was −1.96 close to the cut oV
of −2.0. Under heterogeneity, the overall heterogeneity lod
score at the PTEN locus was 0.18 with an estimated 29% of
the families being the result of PTEN with a 95% confidence
interval of 0% to 79%. Non-parametric linkage analysis
using the NPL statistic of GENEHUNTER was also
performed to guard against a misspecified mode of
inheritance; again, this showed some evidence for allele
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sharing which did not reach formal significance in the region
of PTEN (NPL=0.88, p=0.19). Further, there was no
diVerence in age of onset in those families consistent with
linkage versus those against linkage to PTEN and there was
no trend in terms of the proportion of linked families by
number of aVected males (data not shown).
Linkage analysis of common cancers is complicated by the
presence of heterogeneity. As the majority of our families
consist only of sib pairs, the opportunity of confirming iden-
tity by descent among the aVected brothers is extremely lim-
ited, thus compromising the ability of linkage analysis to
extract convincing evidence of cosegregation. While there is
no formal evidence for linkage, even under multipoint
analysis for a familial prostate cancer gene in the PTEN
region of 10q23, the point estimates for the proportion of
families linked is 29% (95% CI (0.00-0.79)) showing lack of
discrimination from the family material. With these data,
and given the putative role of PTEN in prostate cancer car-
cinogenesis, we decided to pursue PTEN further by
mutation testing in families in which the brothers appeared
to share at least one parental haplotype around PTEN.
All nine exons of the PTEN gene of the youngest
diagnosed member from the remaining 37 families for
whom DNA was available and a Cowden disease positive
control were sequenced in both directions using dRhodam-
ine labelled ddNTPs (Perkin Elmer). Primers were
designed to amplify all coding sequence and at least 15
flanking base pairs.
The IVS8 +32T>G polymorphism in intron 8 reported
by Wang et al24 was found in 27 (73%) of the 37 cases. Forty
five percent of the alleles were the “wild type” G, while the
remaining 55% of alleles were T. Fourteen (38%) of the
cases were TT homozygotes, 13 (35%) were TG heterozy-
gotes, and 10 (27%) were GG homozygotes; these figures
are consistent with Hardy-Weinberg equilibrium (÷2 with 2
df=3.1, p=0.21). No association was found between age of
onset of prostate cancer and genotype (TT v TG v GG)
when the cases were divided into two categories depending
on age of onset being less than or equal to 60 years of age
v 61 years of age or higher (÷2 with 2 df=1.0, p=0.61).
A novel polymorphism (IVS4 −31insT) was found in
intron 4 in one patient, but not in the patient’s brother who
also had prostate cancer, suggesting that it is not important
in prostate cancer susceptibility.
While a missense mutation, c.494G>A (p.165G>E), was
found in exon 6 of the Cowden disease positive control
used, no coding mutations were found in the prostate can-
cer families. In some cases sequencing only extended 15 bp
into non-coding sequence, so non-coding mutations which
may possibly influence RNA splicing or stability may have
gone undetected. The promoter and regulator regions of
PTEN are also unknown at present, so any mutations in
these regions were also not detected. The HPC1 locus in
1q24-25 has been shown to be preferentially involved in
families with four or more aVected cases6 and this might
also be the case for PTEN.
Our linkage results suggest that it is unlikely that PTEN
or any gene nearby in the 10q23.3 region plays any signifi-
cant part as a high penetrance susceptibility gene for pros-
tate cancer. This is consistent with the concept that somatic
mutations in PTEN are a late event in carcinogenesis, as
suggested by Feilotter et al,25 who found very few PTEN
mutations in primary prostate cancer tumours, and the
work of Cairns et al,17 who found a positive correlation
between high prostate tumour grade and presence of
PTEN mutation.
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Mutation analysis of H19 and NAP1L4
(hNAP2) candidate genes and IGF2
DMR2 in Beckwith-Wiedemann
syndrome
EDITOR—Beckwith-Wiedemann syndrome (BWS) is a
human overgrowth disorder with a variable phenotype and
genetic heterogeneity. Recent data indicate that the BWS
locus is subject to genomic imprinting and current evidence
shows that in many patients the disease is associated with
epigenetic lesions of genes on 11p15.5. BWS is characterised
by pre- and postnatal overgrowth, macroglossia, and anterior
abdominal wall defects. Additional, but variable complica-
tions include organomegaly, hypoglycaemia, hemihypertro-
phy, genitourinary abnormalities, and a predisposition to
embryonal tumours in about 5% of patients.1 The genetics
of BWS are complex, but parent of origin eVects, suggesting
genomic imprinting, have been implicated in the pathogen-
esis of three major groups of patients2: (1) for patients (∼2%)
with chromosome 11p15.5 abnormalities, duplications are
of paternal origin and balanced translocations or inversion
breakpoints of maternal origin; (2) in familial cases (∼15% of
all cases) which exhibit more complete penetrance with
maternal transmission; and (3) approximately 20% of
sporadic cases have uniparental disomy (paternal isodisomy)
for chromosome 11p15.5. Cloning of genes in the vicinity of
BWSCR1, the most distal breakpoint cluster associated with
BWS balanced cytogenetic anomalies, and within the area of
minimal disomy present in cases of paternal isodisomy, has
led to the identification of a group of genes as potential can-
didates in the aetiopathology of BWS. Thus, multiple
imprinted genes bounded centromerically by NAP1L4 and
telomerically by L23mrp (RPL23L) have been identified.3–6
For a gene to be a good candidate to account for a
significant number of BWS cases, it should map to this
region and constitute either a paternally expressed growth
promoter or a maternally expressed growth inhibitor.
However, because factors involved in maintaining or
modifying genomic imprints may aVect the epigenotype
and therefore expression status of imprinted genes, it is
possible that an underlying lesion in a non-imprinted gene
may manifest itself as an imprinted trait. Extensive charac-
terisation of IGF2, CDKN1C, and KVLQT1 in BWS
patients has been undertaken already. With the exception
of the involvement of KVLQT1 in some balanced translo-
cations and inversions,7 and IGF2 in paternal
duplications,8 the only mutations within the coding
sequence of a candidate gene described are for
CDKN1C.9–14 In our series, germline CDKN1C mutations
accounted for ∼40% of familial cases and 5% of sporadic
cases.14 This suggests that further BWS genes remain to be
identified. Most sporadic BWS patients show LOI of
IGF215 16 and a candidate BWS gene might cause BWS by
influencing IGF2 imprinting status.
The H19 gene maps approximately 200 kb telomeric of
IGF2 in humans; synteny is conserved in the mouse.17 Data
from human tumours, BWS, and experimental manipu-
lation of the mouse genome indicate that the regulation of
H19 and IGF2 expression is closely and reciprocally
linked.18 For some BWS patients with IGF2 LOI, biallelic
IGF2 expression is associated with suppression of H19
expression and reversal of the normal (unmethylated)
maternal allele methylation patterns, so that both parental
IGF2 and H19 alleles display a paternal methylation
pattern.19 20 However, in other cases with biallelic IGF2
expression, H19 and IGF2 allelic methylation is normal.16
A possible explanation for these observations is that the
maternal H19 RNA is functionally inactivated, not
aVecting its own imprinting status, but leading to loss of
repression of the maternal IGF2 allele. This hypothesis is
consistent with data from the mouse.21
The most centromeric imprinted gene in the 11p15.5
imprinted region is the candidate tumour suppressor gene
TSSC3.22 23 The NAP1L4 gene lies 15 kb 5' of TSSC3 and
encodes a chaperone protein associated with chromatin
assembly and has been shown to bind to core and linker
histones facilitating transfer to the DNA template.24 25
Although NAP1L4 has not been shown to be imprinted to
date, this has not been extensively investigated and tissue
specific or developmentally regulated imprinting cannot be
excluded. NAP1L4 lies within the interval associated with
loss of heterozygosity in Wilms tumour (WT2) and
centromeric to the BWSCR1 breakpoint cluster. It
therefore fulfils one of the criteria for a BWS candidate
gene. The possibility that chromatin structure aVects the
activity and imprinting status of genes is very strong26 and
it is possible that mutations in NAP1L4 might appear to
have an allele specific eVect even if NAP1L4 is not itself
imprinted. Recent studies on a BWS family with a mater-
nally inherited inversion of 11p15.5 suggest that relaxation
of IGF2 imprinting may result from an H19 independent
pathway. In the family reported by Brown et al,27 a
BWSCR1 breakpoint in the region of NAP1L4 was associ-
ated with IGF2 LOI and normal H19 expression.
Importantly, NAP1L4 is expressed in normal kidney and
some Wilms tumours (WT) lacking NAP1L4 expression
show IGF2 LOI (Munroe et al, unpublished observations).
While mutations in NAP1L4 have not been found in spo-
radic Wilms tumours,25 those associated with a genetic
predisposition have not yet been examined, leaving open
the possibility that NAP1L4 mutations in the germline or
somatic mutations early in development may predispose to
the changes seen in BWS and familial WT through an
eVect on the imprinting status of key genes such as IGF2.
Overexpression of Igf2 in mouse development mimics
many features of BWS,28 further implicating IGF2 in BWS.
The IGF2 gene has a conserved diVerentially methylated
region (DMR) in exon 9. This region has been shown in
mice to be consistently methylated on the expressed pater-
nal allele. It has been postulated that the DMR is a meth-
ylation sensitive site for silencer binding. Hence, IGF2 LOI
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could result from mutations that alter the sequence motifs
for silencer binding on the maternal IGF2 allele.
To investigate the molecular mechanism of BWS, we
have performed mutational analysis of the H19 and
NAP1L4 genes and the DMR2 IGF2 region in BWS
patients. Up to 21 subjects (11 male, 10 female) with BWS
were investigated. BWS was diagnosed according to previ-
ously defined criteria: (1) three major features (anterior
abdominal wall defects, macroglossia, and pre-/postnatal
growth >90th centile), or (2) two major features plus three
or more of: characteristic ear signs (ear lobe creases or pos-
terior helical ear pits), facial naevus flammeus, hypoglycae-
mia, nephromegaly, and hemihypertrophy.1 Peripheral
blood samples were obtained from all patients and high
molecular weight genomic DNA was extracted as de-
scribed previously.20
The H19 genomic sequence was numbered as in
Brannan et al.29 Sequencing was performed from nucleo-
tides 650 to 3461. This included 170 bp of sequence 5' to
the transcription initiation site and all five exons and four
introns. The H19 gene was sequenced using genomic DNA
to derive overlapping template fragments approximately
500-700 bp long. Primer sequences used to cover the entire
H19 genomic region in both forward and reverse directions
(and PCR conditions) are available on request. The
sequencing PCR reaction was run according to the ABI
PRISM protocol and H19 sequence data were obtained
using ABI software.
The H19 gene was sequenced in 15 BWS patients with-
out uniparental disomy. These patients represented a vari-
ety of aetiologies of BWS; two patients were familial (with-
out germline CDKN1C mutations) and 13 were sporadic.
Of the latter, two had previously been identified as having
a IGF2/H19 imprinting centre defect (ICD) with H19 pro-
moter hypermethylation and silencing of H19
expression.19 20 Of the remaining 11 sporadic BWS patients
with normal H19 methylation, seven were informative for
allele specific IGF2 mRNA expression analysis; five had
biallelic IGF2 expression with normal H19 expression and
two had biallelic IGF2 expression and absent H19 expres-
sion (but this was not associated with H19 hypermethyla-
tion as in the putative ICD cases).16 Southern analysis (PstI
and SmaI digest) did not show evidence of a genomic rear-
rangement in any case.19 20
Comparison of the H19 sequences in BWS cases and
controls to the sequence published by Brannan et al29 (Gen-
bank Accession number M32053) showed sequence diVer-
ences from the published sequence at five sites that were
present in all patients and controls. These were considered to
represent sequencing errors in the published sequence (table
1). In addition to the consistent sequence changes identified
in all patients and controls, 10 polymorphic sequence
variants were noted in BWS patients. Two of these
nucleotide substitution sites resulting in a RFLP have been
described previously (AluI site at nt 2883 and RsaI site at nt
3241),34 35 but eight novel sequence variants were identified
(table 1): C→T at nt 1531, T→A at nt 1569, G→C at nt
2461, G→C at nt 2791, T→C at nt 2976, T→C at nt 2992,
A→G at nt 3238, and T→C at nt 3281. In each instance,
these changes were also identified in normal controls and
were considered to represent simple polymorphisms.
The intron-exon structure of NAP1L4 has been reported
previously25 and primers were designed to amplify each of
the 14 exons (primer details and conditions are available on
request). PCR products (5 µl) were denatured and electro-
phoresed through an 8% polyacrylamide gel containing 5%
glycerol, using 0.5 × TBE as the running buVer.
Electrophoresis was at 1 watt per gel for 12-18 hours
depending on the size of PCR product. DNA bands were
visualised by silver staining.
A total of 21 BWS patients were analysed for NAP1L4
gene mutations. These included the 15 patients analysed
for H19 gene mutations and a further two familial and four
sporadic cases with normal H19 methylation. Seven
informative cases were known to have biallelic IGF2
expression analysis.16 The coding sequence of the NAP2
gene was amplified in 14 single exon fragments and
analysed by SSCP and ABI sequencing. The only sequence
variant identified was an A→C transversion at +7 of the 3'
exon 2 splice site. This sequence variant does not aVect the
splice site consensus sequence but causes gain/loss of an
RsaI restriction enzyme cutting site (fig 1). This finding
was used to screen for the splice site variant and this was
identified in both BWS cases and controls. We concluded
that this change represented a simple polymorphism.
Primers used to analyse the DMR were forward: 5' CCC
TCT GCC CGT GGA CAT TAG 3' and reverse: 5' GGC
GGG GTC TTG GGT GGG TAG 3'. The PCR
conditions were as for SSCP of NAP1L4 with an annealing
Table 1 Corrections of H19 genomic sequence identified in all patients
(n=23) and controls (n=5)
Site Nucleotide position Correct sequence Polymorphism
Exon 1 1531 C→T
Exon 1 1569 T→A
Exon 1 1737 G→A
Intron 2 2418 +CG
Intron 2 2441 +CGG
Intron 2 2461 G→C
Intron 3 2599 +G
Intron 3 2653 −A
Exon 4 2791 G→C
Exon 5 2894 G→A
Exon 5 2976 T→C
Exon 5 2992 T→C
Exon 5 3238 A→G
Exon 5 3281 T→C
Figure 1 H19 gene A/G polymorphism at nt 3238.
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temperature of 61°C. Half of the PCR product from each
patient was cloned into InVitrogen TA cloning vectors
according to the manufacturer’s instructions (InVitrogen,
BV, The Netherlands). The rest of the PCR product from
each patient was mixed with an equal volume of formamide
loading dye, denatured at 95°C for five minutes, and elec-
trophoresed on 8% PAGE. Sequencing of PCR clones
obtained after the InVitrogen TA cloning was according to
the ABI PRISM protocol described above. Thirteen
patients with BWS (four with IGF2 LOI) were analysed by
SSCP. The expected PCR product was 250 bp, and no dif-
ferences in product were detected by SSCP between any of
the patients. After cloning the PCR products, four clones
per patient were sequenced. In total, 49 clones were
successfully sequenced and all of these were normal.
It appears that mutations or epigenetic lesions in
CDKN1C and IGF2 respectively are involved in the patho-
genesis of BWS. In certain cases, for example, uniparental
disomy, other genes may also be involved. While a signifi-
cant proportion of familial cases (40%) are caused by
germline CDKN1C mutations, the vast majority of
sporadic cases show either uniparental disomy or loss of
imprinting of IGF2.13 15 19 Manipulation of the mouse H19
gene shows that mutations in this locus may result in LOI
of IGF2,30 suggesting that alterations in H19 expression
could directly aVect IGF2 imprinting in humans. BWS
patients with LOI of IGF2 may have normal or absent H19
expression suggesting that a variety of mechanisms
(including mutations) could inactivate H19 function and
lead to IGF2 LOI.16 Despite frequent suggestions that H19
is a candidate BWS gene, H19 mutation analysis has not
been reported previously. As germline H19 deletions have
not been detected in BWS patients with H19/IGF2
imprinting centre defects (ICDs) (IGF2 LOI, H19
hypermethylation, and silencing) or in “H19 null” BWS
patients (IGF2 LOI, absent H19 expression, but normal
H19 methylation), the possibility of mutations within the
H19 gene itself required investigation. In mice, deletion of
the H19 transcription unit leads to loss of imprinting of the
adjacent, normally silent, maternal allele of the IGF2 gene,
whereas the imprinting status of the replacement transcrip-
tion unit is retained.21 Similarly, deletion of sequences
upstream and downstream of H19, including an endoderm
specific enhancer, which aVect its transcription, also aVect
the IGF2 epigenotype both in cis and trans, together with a
switch in the characteristic pattern of IGF2 methylation.18
Taken together, these data suggest a role for H19 and its
surrounding sequences in the regulation of IGF2 imprint-
ing. We therefore analysed the H19 gene to determine if
some BWS patients had H19 mutations causing a silencing
of maternal H19 expression or an expressed but non-
functional H19 RNA. Absent H19 expression might be
associated with large deletions, promoter mutations, or
intragenic mutations which decreased RNA stability. Our
molecular analysis would be expected to detect most intra-
genic mutations and the report of a single nucleotide sub-
stitution in the Xist promoter associated with skewed X
inactivation31 raised the possibility that H19 promoter
mutations might account for the ICD or “H19 null” BWS
patients. Most of the patients we studied had normal H19
promoter methylation analysis, excluding the possibility of
a large promoter deletion in these cases. Sporadic BWS
cases with normal H19 methylation and absent H19
expression could have H19 promoter mutations, but we did
not detect any evidence of such changes in the 170 bp of
sequence 5' to the transcription initiation site that we
sequenced. The finding that most patients were hetero-
zygous for at least one H19 intragenic polymorphic
sequence variant excludes the presence of a complete H19
gene deletion in most cases where expression from both
alleles is suppressed. With the reservation that small, more
distal 5' flanking region mutations may have been missed in
some patients, we conclude that H19 germline mutations
cannot account for the loss of IGF2 imprinting observed in
most BWS cases.16 The mode of action of H19 on IGF2
allele specific transcriptional control is unclear, as it does
not give rise to a translation product. Although it has been
postulated that H19 functions directly or indirectly as a
modifier of chromatin structure in a way similar to that
proposed for the action of XIST in X chromosome gene
inactivation,32 deletion of the mouse H19 gene does not
aVect the imprinting status of Mash2, Cdkn1c, or Kcnq1,33
suggesting that there are at least two imprinting control
centres within this region.
In humans, the observation of biallelic IGF2 expression in
a BWS family with a BWSCR1 breakpoint27 is compatible
with an H19 independent pathway of IGF2 imprinting con-
trol. BWSCR1 rearrangements associated with LOI IGF2
may show loss of a parental allele specific methylation
pattern at KVLQT1, but not more distally at IGF2/H19.36
This observation is consistent with two imprinting control
centres in 11p15.5. Thus, a candidate BWS gene might
function as a cis acting repressor of maternal IGF2
expression and map centromeric to BWSCR1. NAP1L4
(hNAP2) lies at the centromeric boundary of the imprinted
gene cluster on 11p1524 25 and maps centromeric to the
BWSCR1 region in the candidate region for a cis acting
regulator of IGF2 imprinting. To date, evidence of imprint-
ing has not been described for NAP1L4, but its biological
function as a histone chaperone protein provides a possible
mechanism for altering the imprinted status of one or more
genes through potential eVects on chromatin silencing or
activation. Under this model, only the maternal IGF2 allele
would be responsive (because of specific methylation or
chromatin structure imprints) to a cis acting downregulator.
Although NAP1L4 represented a strong BWS candidate
gene, our failure to identify NAP1L4 mutations in a large
cohort of BWS patients strongly suggests that NAP1L4 is
not a major BWS gene.
Having excluded coding sequence mutations in NAP1L4
and major changes in both the coding sequence of H19 and
its immediate promoter region as being frequent patho-
genic lesions in Beckwith-Wiedemann syndrome, we then
considered that mutations in the IGF2 DMR2 would rep-
resent another cause of IGF2 LOI. Consistent with its
putative IGF2 silencer function, DMR2 is more consist-
ently methylated on the paternal allele than on the mater-
nal in tissues in which Igf2 is expressed, and the unmethyl-
ated (maternal) DMR2 sequence is bound by specific
nuclear proteins (AM and WR, unpublished observations).
However, although DMR2 mutations represented a logical
explanation for the subset of BWS patients with IGF2 LOI
and normal H19 imprinting, no mutations were identified.
Thus, the frequent IGF2 LOI found in BWS must
therefore originate in other lesions, either genetic or epige-
netic. It still remains to examine the candidature of TSSC3,
IMPT1, ASCL2, and other loci as they might emerge from
this dense cluster of growth related genes. Such analysis
will identify sequence mutations that lead to altered epige-
netic modifications. However, epimutations (that is,
changes in the epigenetic status without genetic modifica-
tion) could be a mechanism for LOI which would be spo-
radic and potentially be reset in the germline. As mutations
in further BWS candidate genes are excluded as a cause of
LOI IGF2, the likelihood of epimutation being the major
cause of BWS will increase.
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A novel mutation in the CFTR gene
correlates with severe clinical
phenotype in seven Hispanic patients
EDITOR—Cystic fibrosis (CF) is one of the most common
autosomal recessive disorders, with an incidence of one in
every 2000 to 3000 white people. The disease is caused by
mutations in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) gene.1 Over 800 CFTR mutations
have been identified.2 Five mutations in Ashkenazi Jews,3 4
24 in whites,5 and 15 in African-Americans6 account for
97%, 90%, and 75% of CF chromosomes in the respective
populations. In contrast, 90% of CF Spanish alleles were
contributed by as many as 75 mutations, indicating a het-
erogeneous CF genotype in Spain.7 The overall mutation
spectrum and the frequency of common mutations in a
particular population depend on the ethnic background.
For example, the frequency of the W1282X mutation is
1.2% in the white population, but it is as high as 60% in
Ashkenazi Jews.8 That of ÄF508 is 70% in northern Euro-
peans but it is less than 50% in Spanish and Hispanics.7 9 In
order to provide accurate genetic counselling, it is
necessary to determine the prevalent mutations in each
ethnic group. A study of Hispanic CF patients from the
south western United States showed that only 58% of His-
panic CF alleles were detected by screening 23 recurrent
mutations.9 Thus, there is a need to identify the mutations
accounting for the remaining Hispanic CF chromosomes.
In addition, on identification of mutations genotype-
phenotype correlation studies can be facilitated.
The clinical diagnosis of CF has been recently reviewed.10
Although the structure and function of ÄF508 and W1282X
mutant CFTR have been studied, there is a shortage of
genotype-phenotype correlation studies of rare mutations,
particularly the ones that appear to be unique to Hispanic
CF patients. This is partly because of the lack of an eVective
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method for screening the mutations in the large CFTR gene
and because a significant proportion (about 40%) of
Hispanic CF mutations have not been identified.9 We
recently described the clinical features of a patient
homozygous for R1066C and a group of Hispanic patients
with the 3849+10kbC>T mutation.11 12 In an eVort to con-
tinue searching for unknown CF mutations in Hispanic
patients, we have developed an eVective method, temporal
temperature gradient gel electrophoresis (TTGE), to screen
DNA abnormalities in CF chromosomes and have identified
several novel mutations. Here we report the discovery of
3876delA and its clinical presentation in seven Hispanic
patients who were heterozygous for this novel mutation.
DNA samples of 44 CF patients, from 43 unrelated
families, attending the Children’s Hospital at Los Angeles
(CHLA) Cystic Fibrosis Clinic were selected for muta-
tional analysis by TTGE, according to the CCI (Com-
mittee on Clinical Investigations) approved protocol No
90-117. Thirty of the 44 patients were Hispanics, including
two sibs. In this study, “Hispanics” refers to people
originally from Latin America13 and “Spanish” refers to
people living in Spain. These patients have been genotyped
by DNA diagnostic laboratories at the University of
California San Francisco, Baylor College of Medicine, or
Genzyme Corporation, and had either one or both CF
alleles unidentified. Clinical information was obtained
from CHLA CF Clinic records and by reviewing the
patients’ medical charts and consulting clinicians familiar
with the patients’ disease progression.
DNA was extracted from patients’ blood samples. All 27
exons were PCR amplified and analysed with TTGE.14
Exon 20, which contains the 3876delA mutation and its
flanking intron regions were PCR amplified by using prim-
ers 5'GGTCACCATTGAAAGTGT3' (forward) and
5'ATGAGAAAACTGCACTGGA3' (reverse). The PCR
reactions were performed under standard conditions as
described previously.15 PCR products were denatured at
95°C for 30 seconds and slowly cooled down to 45°C for a
period of 45 minutes at a ramp of 1.1°C/minute. The 450
bp PCR product containing the entire exon 20 was
analysed by the TTGE method using the Bio-Rad
DCodeTM mutation detection system according to the
published procedures.15 Electrophoresis was carried out at
130 V at a constant temperature increment of 1.3°C/hour.
The temperature range (48°C to 56.5°C) for this exon 20
PCR fragment was determined empirically with the aid of
computer simulation (MacMelt, Bio-Rad Laboratories).
The DNA samples that showed abnormal banding pat-
terns by TTGE analysis were sequenced using the BigDye
terminator cycle sequencing kit (Perkin-Elmer, Applied
Biosystems) and analysed on ABI Prism 377 DNA
Sequencer (Perkin-Elmer, Applied Biosystems) according
to the manufacturer’s protocols. The sequencing data were
analysed with ABI DNA sequencing analysis software
(version 3.0).
TTGE analysis of exon 20 of the CFTR gene showed an
abnormal banding pattern in seven, including two sibs, out
of 29 unrelated Hispanic patients. Fig 1 (above) illustrates
the results of TTGE analysis. Normal subjects showed a
single band and patients showed three bands. Sequencing
analysis showed a deletion of an A at nucleotide position
3876 of the CFTR gene (fig 1, below). All seven patients
were heterozygous for 3876delA. Two of these patients
were sibs (patients 3 and 4). The remaining 28 patients
screened were from unrelated families. Thus, this novel
mutant allele represents a frequency of 10.3% (6/(29 × 2))
1 2 3 4
Figure 1 (Above) TTGE analysis of the DNA fragment containing CFTR exon 20. Lanes 1 and 4, fragments containing wild type exon 20. Lanes 3
and 4, exon 20 containing fragments amplified from patients 5 and 6. (Below) The upper panel shows the wild type DNA sequence surrounding the
nucleotide position 3876 in the CFTR gene. The underlined “A” is deleted in heterozygous mutant DNA (lower panel).
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in this Hispanic patient group. The 3876delA mutation
was not detected in 14 unrelated non-Hispanic CF patients
examined by TTGE.
Table 1 summarises the clinical findings of these
patients. Five out of the seven patients with 3876delA
mutation were females. Five of them had ÄF508 as the
other mutant allele, one had 1949del84, and one had an
unidentified mutant allele. The current age of the five sur-
viving patients ranged from 4 to 26 years; two had died at
19 and 20 years. The age of diagnosis ranged from 3 weeks
to 7 months, except for patient 6 who was diagnosed at 16
months. In all cases, high levels of sweat chloride (84-142
mmol/l) were detected.
The pulmonary function was measured by percent pre-
dicted FEV1 and percent predicted FVC at diVerent ages.
Patients 1, 5, and 6 showed a drastic drop in both FEV1 and
FVC values within four years, indicating a rapid deteriora-
tion in pulmonary function. Patient 4 was too young to be
tested for FEV1 and FVC. Pulmonary function of patients
2 and 3 has remained normal (>90% predicted values). All
patients had infections of Pseudomonas and Staphylococcus
(table 1). Five of the seven patients who carried this
3876delA mutation developed the syndrome of allergic
bronchopulmonary aspergillosis (ABPA). ABPA is an
immune mediated pulmonary disorder triggered by fungal
colonisation, associated with signs of lung infiltrates,
increased cough, respiratory distress, and wheezing. These
five patients were from unrelated families. The two without
ABPA were the sibs, who had similar clinical symptoms,
including liver disease and gastro-oesophageal reflux.
Overall, these patients showed very similar respiratory
symptoms and common, yet somewhat variable, broncho-
pulmonary impairment.
All seven patients were pancreatic insuYcient (PI) and
required daily treatment of pancreatic enzyme supplement.
Since the other alleles, ÄF508 and 1949del84, render a PI
phenotype,5 10 these results suggest that 3876delA is also a
deleterious mutation with a PI phenotype. Consistently, all
patients had poor growth. Although patient 3 recovered
from the earlier low growth centile at the age of 10, she
suVered respiratory distress as a newborn, portal hyper-
tension, and hyponatraemia, in addition to liver disease and
gastro-oesophageal reflux. Patient 6 developed insulin
dependent diabetes. Patient 5 had cor pulmonale, a late
terminal event of CF.5 She had poor weight gain and died
at the age of 20 of pulmonary failure as did patient 1. In
summary, these observations are consistent with severe
phenotypes, which correlate with the predicted disruption
of NBD2 by 3876delA.
The deleterious frameshift mutation, 3876delA
(L1258X), was detected in six out of 29 unrelated Hispanic
CF patients attending the CHLA CF clinic. This deletion
accounts for about 10% of the total CF alleles in this group.
The frequency of this mutation in the Hispanic CF patients
attending CHLA is similar to that of G542X, only second to
ÄF508. The severity of this group of CF patients is shown by
the early age of diagnosis (average 6 months), the high sweat
chloride (average 105 mmol/l), ABPA, PI, liver disease, cor
pulmonale, and early death. Like those with ÄF508/ÄF508,
ÄF508/W1282X, and W1282X/W1282X, patients with the
3876delA/ÄF508 mutation had variable pulmonary func-
tion. This indicates that other factors may be involved in this
phenotype.8 16 It will be important to follow up patient 4 on
her later development of portal hypertension and more
severe respiratory problems. Meconium ileus, distal intesti-
nal obstruction syndrome (DIOS), and nasal polyps were
not found in this group of patients. However, the observed
poor growth and cholestasis suggest that 3876delA might be
associated with a variable hepatointestinal status.
Patient 1 was a compound heterozygote for 3876delA
and 1949del84. She had a high sweat chloride concentra-
tion of 142 mmol/l, early age of onset (2 months), and
death at the age of 19. The 1949del84 mutation, which
results in an in frame deletion of 26 amino acids located in
the R domain, was originally discovered in a 6 month old
Spanish patient who had ÄF508 on the other mutant
chromosome.17 This patient had a severe clinical course as
well: a sweat chloride concentration of 80 mmol/l, PI, and
both respiratory and digestive problems.17
It is intriguing that after extensive search for CF
mutations in Spanish,7 European,5 Ashkenazi Jewish,3 and
African-American6 populations, the 3876delA mutation
was not discovered. Since most of our Hispanic CF
patients are descendants of people from Mexico and South
Table 1 Clinical presentations of Hispanic cystic fibrosis patients with 3876delA frameshift mutation in the CFTR gene
Patient No
1 2 3 4 5 6 7
Gender F M F F F F M
Genotype 3876delA/1949del84 ÄF508/3876delA ÄF508/3876delA ÄF508/3876delA 3876delA/? ÄF508/3876delA ÄF508/3876delA
Ethnicity Hispanic/Hispanic Hispanic/Hispanic Hispanic/Hispanic Hispanic/Hispanic Hispanic/Hispanic Hispanic/Hispanic Hispanic/Hispanic
Age/age at diag* (19)/2 mth 19/3 wk 10/4 mth 4/6 mth (20)/5m 17/16m 26/7m
Sweat Cl−/age† 142/2 mth 84/1 mth 84/4 mth 99/4 mth 90/5m 96/10y 133/7m
Sweat Cl− (date) 142 (3/9/78) 84 (9/19/79) 84 (2/28/89) 99 (3/24/95) 90 (8/15/78) 96 (12/4/91) 133 (1/4/74)
FEV1‡/age 101/15, 37/18 103/14, 114/18 79/7.5, 113/10 N/A 102/15, 20/19 105/12, 33/16 34/20, 30/23
FVC§/age 96/15, 20/18 96/14, 97/18 72/7.5, 137/10 N/A 96/15, 30/19 103/12, 22/16 64/20, 63/23
Pancreatic status¶ PI PI PI PI PI PI PI
Ht/wt/age** 5/5/15, 5/5/18 5/22/14, 5/6/19 10/50/1.5, 95/95/10 7/5/0.5, 16/10/4 5/6.5/15, 5/5/18 5/5/12, 5/5/17 5/5/20, 5/5/25
Bacterial
colonisation
P aeruginosa P aeruginosa P aeruginosa P aeruginosa P aeruginosa P aeruginosa P aeruginosa
S aureus S aureus S aureus S aureus S aureus S aureus
S maltophilia
Respiratory ABPA†† ABPA Distress as
newborn
ABPA ABPA, persistent
cough
ABPA
Gastrointestinal
status
Gastro-oesophageal
reflux
Gastro-oesophageal
reflux
Gastro-oesophageal
reflux
Other
complications
Death Pneumonia Liver disease at 6,
portal hypertension
at 7, malabsorption,
hyponatraemia
Liver disease at 10
months, malnutrition,
requiring G tube at
11 months of age
Cor pulmonale,
ovarian teratoma,
death
Insulin dependent
diabetesBronchoscopy at
11
Hyponatraemia
*Age at diagnosis in years; y, year; mth, month; wk, week. The number in parentheses denotes the age at death.
†Concentration of sweat chloride is in mmol/l; y, year; mth, month.
‡FEV1 denotes forced expiratory volume in one second, percentage predicted/age at testing in years.
§FVC is a measurement of forced vital capacity, percentage predicted/age at testing in years.
¶PI, Pancreatic insuYciency, as determined by the patients’ dependence on pancreatic enzyme supplements.
**Ht, height, and wt, weight, are both in percentage of normal. Age is in years.
††Allergic bronchopulmonary aspergillosis.
Patients 3 and 4 are sibs.
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America, the 3876delA mutation might be derived from
native Mexicans. Further haplotype studies will be
necessary to support this hypothesis. It is concluded that
3876delA is one of the common mutations in Hispanic CF
patients and should be included in the routine mutational
analysis of Hispanic CF patients. This mutation does not
result in change of restriction site. The allele specific oligo-
nucleotide (ASO) dot blot analysis would be a simple
method for quick diagnosis of this mutation. The
genotype-phenotype correlation will greatly assist genetic
counselling regarding the prognosis of CF patients.
Like other ABC transporters, the CFTR chloride chan-
nel contains two nucleotide binding domains, NBD1 and
NBD2, both of which have the consensus sequences for
Walker A and Walker B motifs.18 Between the two NBDs is
a highly positively charged regulatory (R) domain, whose
phosphorylation by protein kinase A modulates the
interaction between the NBDs.19 The 3876delA mutation
resides in the very centre of the Walker A motif in the
NBD2, resulting in the alteration of the highly conserved
amino acid sequence in the second half of this motif, start-
ing at amino acid S1248 (fig 2). It also causes a premature
protein termination at L1258, 10 amino acids downstream
of the mutation site, resulting in the loss of six conserved
sequence blocks including the Walker B motif which hosts
the ã phosphate binding pocket.1 According to the
proposed secondary structure assignment for NBD2,20 the
3876delA mutation would abolish all the seven helices in
NBD2. Since ATP hydrolysis at NBD2 terminates a burst
of activities associated with opening the channel, loss of
NBD2 would confer a loss of the gating control.21
A recent study shows that the Walker A motif in NBD2
is more solvent accessible than that in NBD1, suggesting a
diVerence in structure and function for the two NBDs.22 In
addition to 3876delA, a few other mutations in NBD2,
including G1244E, S1255P, S1255X, 3905insT, W1282X,
N1303K, and G1349D, all result in a PI phenotype.5 23 It
should be noted that S1255P, S1255X, 3905insT, and
3876delA are all clustered around the Walker A motif.
However, whether the PI phenotype is caused by the loss of
gating control in NBD2 is not clear. Evidence is emerging
for the involvement of the C-terminus of CFTR in some
other biological processes. It has been shown that there is a
specific and tight binding between the CFTR C-terminus
and the Na+-H+ exchanger regulatory factor.15 The
3876delA mutation oVers a good opportunity for under-
standing the molecular mechanisms of CF pathogenesis.
This study is part of the project “Molecular and Clinical Studies of CF Patients
in Southern California” supported by the Webb Berger Foundation.
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The continuing failure to recognise
Alström syndrome and further
evidence of genetic homogeneity
EDITOR—A disorder may be prone to misdiagnosis or
underdiagnosis when it is rare, has multiple presentations,
a slowly evolving phenotype, or no pathognomonic test.
Such would seem to be the case for Alström syndrome.1 We
have recently diagnosed this disorder in seven members of
six Pakistani families. In none of the aVected subjects had
the correct diagnosis previously been made. Instead the
given diagnoses were Bardet-Biedl syndrome, Leber’s
amaurosis, a type of retinitis pigmentosa, sporadic dilated
cardiomyopathy, an unidentified mitochondrial disorder,
and Usher syndrome. This experience is not unusual since
in a recent British study of Alström syndrome patients,
seven of 22 had initially been incorrectly diagnosed.2
The clinical features of Alström syndrome are well illus-
trated in our families.3 Progressive visual impairment pre-
sented in the first 6 months of life as photophobia and nys-
tagmus, advancing to a cone-rod dystrophy and registered
blindness in the second decade. Truncal obesity and acan-
thosis nigricans were evident before 5 years, but became
more obvious after puberty. Male external genitalia
remained small (especially in males with obvious gynaeco-
mastia). All patients were of short stature by the age of 8
but none manifested diabetes mellitus, although this has
previously been reported as a common feature.1 Sen-
sorineural deafness presented late in the first decade. Renal
failure frequently develops during the third decade, 3 this
being the cause of death in three family members suspected
to have had Alström syndrome. A dilated cardiomyopathy
can also occur at any age and often spontaneously
improves. It may present in the first year of life before other
disease features and did so in two aVected subjects in the
families reported here.
After further pedigree determination, we found that four
of the families were related (fig 1) and that the remaining
two families were also part of a larger pedigree. Genotyping
showed that polymorphic markers D2S292, D2S2113,
D2S2110, and D2S2112 were homozygous in all aVected
subjects. Markers D2S136 and D2S286 delineate the criti-
cal region of 10 cM in our families. D2S136 lies 4 cM telo-
meric to the minimal critical region reported by Macari et
al,5 while our centromeric boundary (D2S286) is coinci-
dent with that of Collin et al.4 Using MLINK,6 a maximum
two point lod score of +4.62 was obtained for the marker
D2S2113 at è=0. Genetic linkage analysis thus confirmed
our clinical diagnosis and the recent reports of an Alström
syndrome gene location at chromosome 2p13.4 5
Our experience suggests that Alström syndrome should
be considered in all cases of early onset dilated cardiomyo-
pathy and cone-rod dystrophy/atypical Leber’s amaurosis.
Follow up should be undertaken to seek additional features
of this autosomal recessive disorder with a 1 in 4
recurrence risk. To date, all published Alström syndrome
families have shown linkage to chromosome 2p13,
suggesting that the disorder is genetically homogeneous.
Now that a locus has been identified, gene cloning and
mutation detection can be anticipated which will allow
diagnostic testing in any suspected case of Alström
syndrome. Functional analysis of the cloned gene may also
provide wider insights into the pathogenesis of dilated car-
diomyopathy and maturity onset diabetes mellitus.
This study was supported by the British Heart Foundation. Research in the
authors’ laboratories is also supported by the West Riding Medical Research
Trust, the Medical Research Council, the Wellcome Trust, Action Research,
Northern and Yorkshire Regional Health Authority, Yorkshire Cancer Research,
and the Birth Defects Foundation.
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Figure 1 The simplest genealogical links between aVected family members of family 1.
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Clinical and radiographic features of a
family with hypochondroplasia owing to
a novel Asn540Ser mutation in the
fibroblast growth factor receptor 3 gene
EDITOR—Hypochondroplasia is a mild, autosomal domi-
nant skeletal dysplasia. The relative dearth of specific clini-
cal manifestations and the absence of pathognomonic
radiographic features often make the diagnosis of hypo-
chondroplasia diYcult.1–4 Short limbed dwarfism is rarely
recognised before the age of 2 years and is usually mild
with heights up to the low normal range. Muscular body
build, macrocephaly with mild frontal bossing, and lumbar
hyperlordosis are frequently reported. The radiographic
features are variable and can be almost normal in mildly
aVected subjects.4 They most typically include no change
or decrease in the interpedicular distance from the first to
the fifth lumbar vertebral bodies, anteroposterior shorten-
ing of the lumbar pedicles, short iliac bones with flat
acetabular roof, small sacrosciatic notches, short tubular
bones, short and broad femoral necks, and relative elonga-
tion of the distal or proximal portion of the fibula.2 4 Proof
that achondroplasia and hypochondroplasia are allelic dis-
orders came with the discovery that both conditions map to
the distal short arm of chromosome 4.5 6 Subsequently,
Figure 1 The proband at 8 years 9 months of age. Front and side views illustrate prominent forehead, low nasal bridge, anteroposteriorly flattened thorax,
and lumbar hyperlordosis.
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mutation analysis of the FGFR3 gene, located in the
4p16.3 region, showed a recurrent mutation (N540K) in
several unrelated hypochondroplasia patients.7 8 Recently,
two novel mutations in the same region of the FGFR3 gene
causing hypochondroplasia have been identified: N540T in
a Dutch family and I538V in a Swedish kindred.9 10 In
some sporadic patients and families with clinical or radio-
graphic features of hypochondroplasia, a causal involve-
ment of the FGFR3 gene has been ruled out, suggesting
locus heterogeneity.11–14
We report here a novel N540S mutation in the FGFR3
gene and provide evidence that this mutation causes hypo-
chondroplasia in a Belgian family. The proband is an 8 year
old girl referred to the paediatric endocrinologist because
of short stature. She was born after an uncomplicated
pregnancy to young and non-consanguineous Belgian
parents. Birth weight was 3350 g (50th centile) and length
49 cm (25th-50th centile). Psychomotor development was
normal. She presented at the age of 8 years 9 months with
mild disproportionate short stature. Anthropometric mea-
Figure 2 Radiographs of the spine and pelvis in the proband at the age of 8 years 9 months. (A) The pelvis is normal. (B) Anteroposterior view of the
lumbar spine shows minimal increase in interpedicular distance from the first to fifth lumbar vertebra. (C) Lateral view of the lumbosacral spine illustrates
mild anteroposterior shortening of the lumbar pedicles and accentuated lumbar lordosis with the sacrum tilted more horizontally.
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surements showed a height of 120.1 cm (3rd centile=123
cm), weight 23.8 kg (3rd centile), head circumference 52.5
cm (50th-75th centile), span 120 cm, lower segment 58 cm
(upper to lower segment ratio 1.07), hand length 13.2 cm
(3rd centile), and foot length 18 cm (3rd centile=18.7 cm).
In addition, a prominent forehead, low nasal bridge,
anteroposteriorly flattened thorax, and lumbar hyperlordo-
sis were found on physical examination (fig 1). Radio-
graphic study of the skeleton showed mild shortening of
the tubular bones, minimal increase in lumbar interpedicu-
lar distance, anteroposterior shortening of the lumbar
pedicles and vertebral bodies, and accentuated lumbar lor-
dosis with horizontally tilted sacrum (fig 2). The 37 year
old father is also short with a height of 167.9 cm (3rd-25th
centile), head circumference 60.3 cm (98th centile=58
cm), span 175 cm, and lower segment 82 cm (upper to
lower segment ratio 1.05). His clinical phenotype is
characterised by macrocephaly with a prominent forehead,
low nasal bridge, muscular build, and broad thorax. Radio-
graphs of the skeleton showed mild shortening of the tubu-
lar bones, increase in lumbar interpedicular distance,
anteroposterior shortening of the lumbar pedicles and ver-
tebral bodies, long proximal portion of the fibula, and
remarkably short femoral necks (fig 3).
Because the clinical and radiographic features in both
father and daughter suggested the diagnosis of hypochon-
droplasia, sequence analysis of the tyrosine kinase I domain
of the FGFR3 gene was performed. Genomic DNA was
extracted from peripheral blood leucocytes by the Qiagen-
Blood miniprep kit (Qiagen Inc, Chatworth, CA).
Oligonucleotide primers and PCR conditions for amplifi-
cation of exon 11 and part of exon 12 were used as previ-
ously described.8 The amplified DNA fragments were
cloned using the TA cloning kit (Invitrogen) and
sequenced. This analysis showed heterozygosity for an A to
G transition in both patients, resulting in substitution of
serine for asparagine at position 540 (N540S) of the
FGFR3 protein (fig 4). This nucleotide sequence change
creates a cleavage site for the restriction endonuclease
MwoI. Restriction analysis of amplified genomic DNA
fragments confirmed that both patients were heterozygous
for the mutation and that neither unaVected family mem-
bers nor any of a panel of 100 unrelated, healthy controls
carried the nucleotide change (data not shown).
Both subjects are mildly but variably aVected. The
radiographic changes in the daughter are subtle whereas
the father, with a height in the low normal range, shows
convincing radiological features of hypochondroplasia. It is
highly likely that this mutation is responsible for hypochon-
droplasia based on the following strong arguments. First,
the mutation is not present in the unaVected family mem-
bers or in 100 unrelated, healthy controls. Second, the
mutation resides in a highly conserved region when
comparing all four human FGFRs.15 Third, the nucleotide
change implies the replacement of the same amino acid as
in the common N540K mutation, which has been clearly
established to cause hypochondroplasia. Fourth, substitu-
tion of the same asparagine by threonine, a neutral and
Figure 3 Radiographs of the spine, pelvis, and knees in the father aged 37 years. (A) Short femoral necks on the frontal radiographs of the pelvis. (hips
rotated outwards are shown) (B) Normal increase of interpedicular distances in lumbar spine. Anteroposterior shortening of the lumbar pedicles and
vertebral bodies. (C) Elongation of the proximal end of the left fibula (top shown by arrow).
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polar amino acid similar to serine, has been reported in
hypochondroplasia.9
The identification of yet another novel mutation, result-
ing in the substitution of asparagine in position 540 of the
FGFR3 protein and with hypochondroplasia as the pheno-
type, emphasises the important role of this specific site of
the tyrosine kinase I domain in the pathogenesis of the dis-
order. Therefore, in patients with clinical/radiographic fea-
tures of hypochondroplasia in whom restriction analysis or
mutation detection methods do not show the presence of
the common N540K mutation, sequence analysis of the
tyrosine kinase I domain of the FGFR3 gene should be
performed to exclude other nucleotide changes in that
region.
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Screening British CADASIL families
for mutations in the NOTCH3 gene
EDITOR—CADASIL (Cerebral Autosomal Dominant Ar-
teriopathy with Subcortical Infarcts and Leucoencepha-
lopathy) is a hereditary form of multi-infarct vascular
dementia.1 Clinical symptoms often present in middle
adult life (30-50 years of age) and include recurrent
subcortical ischaemic strokes, migraine with or without
aura, major psychiatric symptoms, and dementia. Mag-
netic resonance imaging (MRI) shows high intensity signal
lesions, often confluent, and areas of cystic degeneration of
the subcortical white matter and basal ganglia. Pathologi-
cal examination shows multiple, small, deep cerebral
infarcts, leucoencephalopathy, and a non-atherosclerotic,
non-amyloid angiopathy involving mainly the small, deep,
perforating cerebral arterioles. Severe alterations of vascu-
lar smooth muscle cells are evident on ultrastructural
analysis.
The term CADASIL was adopted after linkage of
French families with these symptoms to chromosome 19,2 3
but families with many of the features of CADASIL had
been described by Worster-Drought et al4 5 in the 1930s as
familial presenile dementia with spastic paralysis, by Sour-
ander and Walinder6 as hereditary multi-infarct dementia,
and by Stevens et al7 as chronic familial vascular encepha-
lopathy. In 1996, the responsible gene was identified as
NOTCH3,8 a member of the Notch family of signalling
proteins originally identified in Drosophila.9
Notch and Notch homologues control the ability of
non-terminally diVerentiated cells to respond to
diVerentiation/proliferation signals through local cell
interactions.10 They are transmembrane proteins with dis-
tinct extracellular and intracellular domains. Notch is acti-
vated by binding of a ligand to the extracellular so-called
epidermal growth factor (EGF) repeats.11 This is thought
to release the intracellular domain which translocates to
the nucleus to regulate the transcription of genes that ulti-
mately determine cell fate.12 13
To date, 26 separate mutations have been found in
NOTCH3, 24 as described by Joutel et al14 in the French
families and two additional mutations from American
families, as reported by Meeks et al.15 Twelve of these
mutations are clustered in exon 4. All of these mutations
predict the introduction or replacement of cysteine
residues in the extracellular EGF repeat domain. CA-
DASIL has also been reported in Dutch,16 German,17
Swiss,18 Italian,19 20 American,21 22 and Japanese families.23
We report here the results of linkage analysis and screening
for mutations in British families with a diagnosis of
CADASIL.
DNA was available from four multiplex families from the
central belt of Scotland, all of Scottish ancestry, a family
from south west England of English ancestry, and one fur-
ther isolated subject from Scotland with suspected
CADASIL. We classified the diagnosis of CADASIL into
definite, when there was neuropathological confirmation or
evidence of genetic linkage to chromosome 19p12 or both,
and probable, where there were clear clinical symptoms
and MRI findings typical of CADASIL plus a positive
family history. The clinical-demographic details and results
described in the text below are summarised in table 1. In
spite of extensive genealogical investigations we were
unable to find a common ancestor for any of the families
described.
Families 1 and 2, both Scottish, had suYcient meioses
available to perform analysis of genetic linkage to chromo-
some 19p12. We genotyped the families on a Perkin Elmer
Applied Biosystems (PE ABI) 377 automated genotyper
with 5' FAM labelled primers for six polymorphic micro-
satellite markers, D19S226, D19S411, D19S885,
D19S199, D19S923, and D19S841 flanking the NOTCH3
gene (GDB accession numbers 188569, 199752, 608544,
182271, 611676, and 593357, respectively), and analysed
the results using Perkin Elmer Genescan software (version
2.1).
Clear genetic linkage to chromosome 19p12 was found in
both families. Family 2 was originally reported not to be
linked to chromosome 19.24 However, further characterisa-
tion of the phenotypes in these families by MRI scanning,
which had not been performed at the time of the initial
reporting, required us to reclassify several cases showing key
recombinants. We also determined haplotypes at NOTCH3
in the other multiplex families and found the same patterns
of microsatellite allele sizes for families 3 and 4.
We then sequenced exon 4 of the NOTCH3 gene (GDB
accession number AF058883) in all our families, by auto-
mated sequencing of PCR products. After checking size
and yield on 1% agarose gel electrophoresis, PCR products
were purified using Centrikon™ columns. Purified PCR
products were sequenced by automated cycle sequencing
using PE ABI BigDye™ chemistry. The products were run
on polyacrylamide gels on a PE ABI 377 automated
sequencer and analysed using PE ABI Factura (2.0.1) and
Sequence Navigator (1.1) software.
Table 1 Diagnostic details for families studied
Diagnosis
No of
cases Neuropathology
Clinical
symptoms MRI
Family
history
Linkage
analysis
Mutations
Nucleotide Amino acid
Family 1 Definite 19 Definite 1, 2, 3, 4 Typical Yes Pos C583T R171C
Family 2 Definite 21 Definite 1, 2, 3, 4 Typical Yes Pos C475T R135C
Family 3 Probable 2 NA 1, 3, 4 Typical Yes NA C499T R143C
Family 4 Probable 4 NA 1, 2, 3 Typical Yes NA C499T R143C
Family 5 Probable 3 NA 1, 3, 4 Typical Yes NA C622T R184C
Proband family 6 Probable 1 NA 1, 2 Typical Yes NA C622T R184C
NA: not available.
Clinical symptoms: (1) strokes, (2) psychiatric symptoms, (3) migraine with or without aura, (4) dementia.
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The CADASIL disease mutation was found in exon 4 in
all families in positions described earlier14 (table 1). The
sequencing results corresponded with the genetic linkage
analysis for all aVected and unaVected members of families
1 and 2. The results also agreed with the predicted aVected
status based on clinical and MRI data for members of
families 3-6. The C499T mutation coding for the R143C
amino acid substitution is shared between families 3 and 4.
Since they share the same haplotype it is likely that the
mutation has the same ancestral origin.
In addition to the mutations, the sequencing also
detected reported polymorphisms.14 For example, the
G684A polymorphism in exon 4 was found with a
frequency that matches the 0.17 described by Joutel et al.14
In conclusion, our results confirm the broad geographi-
cal occurrence of CADASIL in Europe. It is conceivable
that this rare Mendelian type stroke is still largely
underdiagnosed and mutation analysis will lead to an
increase in the number of diagnosed cases.
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Correlation between mutations and age
in cystic fibrosis in a French Canadian
population
EDITOR—Cystic fibrosis (CF) is the most common, lethal,
autosomal recessive childhood disorder in the white popu-
lation, occurring in about 1 in 2500 live births.1 The inci-
dence (1975-1995) is 1 in 936 live births, with a carrier rate
of 1 in 15 in inhabitants of Saguenay-Lac-Saint-Jean
(SLSJ), a geographically isolated region in north eastern
Quebec.2
One hundred and sixty three patients in 143 families are
known at the “Clinique de la Fibrose Kystique” in
Chicoutimi (Saguenay), which is the referral centre for the
whole region (285 000 inhabitants) and has followed all the
CF patients but one since 1973. Molecular characterisa-
tion has been performed on all identified living CF
patients.3 Three mutations account for 94.4% of the CF
chromosomes; these are the ÄF508 (64.1%), 621+1G→T
(22.6%), and A455E (7.7%) mutations.
SLSJ oVers a unique opportunity to investigate whether
there is a relationship between CFTR genotype, mutation,
and survival. Indeed, all the CF patients are followed by the
same multidisciplinary team, one of the paediatricians
having been aYliated with the clinic since its opening.
Although therapy has improved over this period of time,
there is continuity and homogeneity in the follow up and
treatment. Furthermore, the presence of three mutations,
two severe and one mild, at high frequencies allowed us to
compare diVerent classes of CFTR mutations.
Data collected on each patient were extracted from the
files kept at the CF clinic in Chicoutimi where the patients
come on a regular basis (approximately every two months)
as outpatients for advice, follow up, and treatment. This
medical visit consists of a physical examination, a growth
and nutritional status evaluation, pulmonary function tests
by spirometry, and a sputum culture. This phase of data
gathering has been described in detail elsewhere.4
We only considered the genotyped patients, alive or dead
after 1973, diagnosed before they reached 5 years old, in
order to have a more homogeneous group consisting of
patients having suYcient clinical signs and symptoms for
the diagnosis to be made early in life. The Kaplan-Meier
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survival analysis was used to test whether there were
significant diVerences (p<0.05) in the cumulative survival
of the CF patients carrying one of the three main
mutations.
Table lA shows the distribution of the 137 CF patients,
including 15 dead (10.9%), by age groups and genotypes.
It does not include 10 CF patients who died between 1973
and 1989 and were not genotyped. The proportion of
patients homozygous for ÄF508 remains quite constant
between the three age groups, whereas there is a decline in
that of the patients carrying the 621+1G→T/ÄF508 geno-
type and an increase of those having a ÄF508/A455E or
621+1G→T/A455E genotype.
Because of the small numbers involved, the 15 genotypes
were grouped according to the three main CFTR mutations
(table 1B). The A455E mutation group contains all the
patients with that mutation, independently of the second
mutation composing their genotype. The CF patients
carrying the 621+1G→T mutation, but not A455E, were
included in a unique group. Patients homozygous or com-
pound heterozygous for the ÄF508 mutation, without the
621+1G→T or the A455E mutation, were grouped
together. We observed an increase of A455E and a
depletion of 621+1G→T at older age groups, whereas the
frequency of the ÄF508 mutation stayed constant (table
1B).
Fig 1 shows the cumulative survival by mutation. The
Kaplan-Meier survival analysis could not be performed
considering the three mutations because there were no
dead patients in the A455E group. No significant
diVerence was found between the ÄF508 and the
621+1G→T groups (p>0.05).
Evaluating survival as a function of the CFTR genotype
or mutation requires that patients have the same access to
medical care and had been diagnosed very early (before 5
years old). Our approach is diVerent from those who
determined the genotypes of adult patients or patients
diagnosed at a later age5–7 and found rare mutations.
Indeed, those patients should have a less severe phenotype
or disease evolution, which does, in part, correlate with
milder mutations.
The ÄF508 and 621+1G→T alleles are known to be
severe mutations conferring pancreatic insuYciency when
they are combined with another severe mutation.4 8 9 The
A455E allele is a mild mutation associated with pancreatic
suYciency and exerts a dominant eVect on the severe
mutations. Compound heterozygotes for the A455E muta-
tion have a milder pulmonary disease, no meconium ileus,
and no late complications, such as diabetes and liver
cirrhosis.2 Therefore, since pulmonary insuYciency is the
major cause of mortality in cystic fibrosis, it is not
unexpected that no CF patients carrying the A455E muta-
tion have died unlike the 13% of those with two severe
mutations.
Since our series is small, the results should be considered
as preliminary. However, it appears that survival is not only
related to good care and treatment, but is also, at least in
part, genetically determined.
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Table 1 Distribution of cystic fibrosis patients diagnosed before the age of 5 by age groups in Saguenay-Lac-Saint-Jean,
(A) by genotype, (B) by mutation
0–10 years 10.1–20 years Over 20 years All ages
No % No % No % No %
(A) Genotype
ÄF508/ÄF508 15 (1) 40.5 21 (2) 36.2 18 (3) 42.9 54 (6) 39.4
ÄF508/621+1G→T 12 (1) 32.4 16 (1) 27.6 10 (1*) 23.8 38 (3*) 27.7
ÄF508/A455E 1 2.7 6 10.3 5 11.9 12 8.8
ÄF508/I148T 1 2.7 1 1.7 2 1.5
ÄF508/Y1092X 3 (1) 5.2 1 2.4 4 (1) 2.9
ÄF508/Q890X 1 2.4 1 0.7
ÄF508/R1158X 1 2.4 1 0.7
621+1G→T/621+1G→T 2 (1) 5.4 4 6.9 1 2.4 7 (1) 5.1
621+1G→T/A455E 1 2.7 4 6.9 3 7.1 8 5.8
621+1G→T/711+1G→T 2 (1) 5.4 2 (1) 3.4 4 (2) 2.9
621+1G→T/Y1092X 1 2.7 1 0.7
621+1G→T/S489X 1 2.7 1 0.7
621+1G→T/G85E 1 (1) 1.7 1 (1) 2.4 2 (2) 1.5
A455E/R117C 1 2.7 1 0.7
N1303K/I148T 1 2.4 1 0.7
Total 37 58 42 137
Death (4) 10.8 (6) 10.3 (5*) 11.9 (15*) 10.9
(B) Mutation
ÄF508 16 (1) 43.2 25 (3) 43.1 21 (3) 51.2 62 (7) 45.6
621+1G→T 18 (3) 48.6 23 (3) 39.7 12 (2*) 29.3 53 (8*) 39.0
A455E 3 8.1 10 17.2 8 19.5 21 15.4
Total 37 58 41 136
Death (4) 10.8 (6) 10.3 (5*) (12.2) (15*) (11.0)
( ): Number of deaths.
*Including one accidental death.
Figure 1 Survival analysis (Kaplan-Meier cumulative) for three CFTR
mutations in a French Canadian population.
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The heritability of high myopia: a
reanalysis of Goldschmidt’s data
EDITOR—The prevalence of myopia varies widely.1–3 In
western Europe and the United States the prevalence of
myopia is estimated as 10-25%, while in parts of Asia the
prevalence is often much higher.4–9 High myopia (usually
defined as a refractive error>−6.00 D) has a prevalence of
0.5-2.5% in western Europe and the USA and is second
only to diabetes as the most common cause of blindness in
the working age population.2 10 11 Here, to distinguish it
from high myopia, myopia <−6.00 D will be referred to as
“low myopia”.
There is compelling evidence that both environmental
and genetic factors are involved in the aetiology of
myopia.12 An influential series of population studies by
Young et al13 14 reported a dramatic increase in the
prevalence of myopia in the generation of Alaskan Eskimos
first exposed to compulsory education and a “westernised”
environment during their childhood. Independent popula-
tion studies targeting other isolated communities that had
been exposed to similar changes in environment corrobo-
rated these findings15 16 Parent-oVspring heritability esti-
mates in these studies were generally low (table 1), while
sib-sib heritability was usually high, suggesting that
environmental factors had dominated any influence of
genetics in determining refractive error. Dominance of
environmental factors over genetic factors is also evident in
“form deprivation” myopia. This condition develops when
visual clarity is severely compromised during a critical
period of postnatal development.17–20
The genetic contribution towards the development of
myopia has been investigated in both population studies
(table 1) and twin studies (table 2), and has been reviewed
previously.12 21 While these investigations have suggested
that myopia is genetically determined to some extent, there
has been no consensus of opinion regarding whether or not
myopia has diVerent aetiological causes, nor on the mode
or modes of inheritance of the disease. Nevertheless, the
reviews of Bear12 and Goss et al21 suggest that myopia is
likely to be aetiologically heterogeneous and that, in the
case of high myopia, both polygenic and various mono-
genic forms of inheritance may be involved.
In the last decade, the molecular genetics of myopia has
begun to be explored, and these investigations have
increased our understanding of myopia considerably. Early
studies in this area identified the myopias that occur as part
of the rare connective tissue diseases Marfan syndrome and
Stickler syndrome types 1 and 2, tracing the conditions to
defects in the fibrillin, COL2A1, and COL11A1 genes,
respectively.22–24 In addition, the loci of the X linked Åland
Island eye disease and the autosomal recessive Knobloch
syndrome were mapped to Xp11 and 21q22.3,
respectively.25 26 In the case of simple myopia (myopia that
Table 1 Heritability estimates for myopia from family studies
Study Heritability Relationship Sample No Comments
Sorsby et al45 h2 = 0.45 Parent-oVspring 28 families UK population
h2 = 0.49 Midparent-oVspring 106 subjects
h2 = 0.72 Sib-sib
Nakajima et al46 h2 = 0.16 Parent-oVspring 162 pairs of subjects
h2 = 0.42 Parent-oVspring 35 pairs of subjects Subset chosen as having been “measured
more accurately”
Young et al13 h2 = 0.10 Parent-oVspring 197 subjects Eskimo population. Environment related
shift in myopia prevalence with age. Only
analysed a subset of population
h2 = 0.98 Sib-sib
Young and Leary14 h2 = 0.46 Midparent-oVspring 1083 subjects Eskimo population. Environment related
shift in myopia prevalence with age
Keller47 h2 = 0.37 Parent-oVspring 289 pairs of subjects US population
Hegmann et al48 h2 = 0.24 Midparent-oVspring 163 families US population. Randomly selected families
866 subjects
Alsbirk15 h2 = 0.14 Parent-oVspring 483 subjects Eskimo population. Environment related
shift in myopia prevalence with ageh2 = 0.04 Midparent-oVspring
h2 = 0.50 Sib-sib
Johnson et al49 h2 = -0.03 Parent-oVspring 76 families Mixed Eskimo and white population.
Environment related shift in myopia
prevalence with age. Only analysed a subset
of population
Ashton36 h2 = 0.49 Midparent-oVspring 377 families Significant shift in refraction with age
h2 = 0.74 Sib-sib
h2 = heritability, US = United States, UK = United Kingdom.
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occurs in the absence of other abnormalities), Olmedo et
al27 and Pintado et al28 were the first to provide evidence for
genetic diVerences between high and low forms. More
recently, genetic linkage studies have identified two discrete
loci for dominantly inherited simple high myopia.29 30 The
latter work has confirmed the aetiologically heterologous
nature of simple high myopia for the first time.
While there has been numerous attempts to estimate the
heritability of myopia (tables 1 and 2), none of these stud-
ies has calculated a heritability estimate solely for high
myopia. Given the likelihood of aetiological diVerences
between high and low myopia, we sought to calculate such
a heritability estimate. In view of the probable polygenic
nature of most high myopia,21 we also calculated a risk ratio
for sibs (ës) for high myopia. In both cases, these
calculations were based on a reanalysis of the data of
Goldschmidt.5
Methods. The 1968 study by the Danish geneticist Ernst
Goldschmidt5 is particularly informative because the popu-
lation groups investigated were large and chosen without
bias. One of the two samples studied by Goldschmidt was
the population of children born in Copenhagen in 1948. At
the time of examination, these children were aged 13 to 14
years. The size of the population group was estimated to be
9700, and 9243 of these were surveyed (95%). The school
medical records of the 9243 children were screened to iden-
tify those likely to be myopic (specifically those already
wearing spectacles or with reduced visual acuity). Since all
children in the population group were examined by a school
medical oYcer on an annual basis, it seems unlikely that any
cases of high myopia would have been missed. Subjective
refraction was measured in sphere/cylinder form for 1039 of
the 1111 children identified as potential myopes (for the 72
potential myopes who were not examined, Goldschmidt
predicted that 62 were myopic based on their medical
records). Cycloplegia was only used “where the indications
were uncertain or there was an obvious discrepancy between
the uncorrected and corrected vision”. Myopes with an ocu-
lar refraction in one eye of <−6.00 D were classified by
Goldschmidt as high myopes, and the ocular refractions of
their parents and sibs were also measured and reported.
Goldschmidt calculated the prevalence of myopia in his
child population group to be 9.5%. However, for
subsequent analyses regarding the diVerent degrees of
myopia, he confined his analysis to numbers of aVected
eyes rather than the number of aVected people. Since the
latter figure is required for calculations of a risk ratio for
high myopia (see below), we have reanalysed Gold-
schmidt’s data in order to estimate the prevalence of highly
myopic subjects, as follows. Of the 9243 children screened
by Goldschmidt, 877 were myopic. In a subset of 815 of
these myopes (see above), 39 were myopic by<−6.00 D in
at least one eye. Thus the prevalence of high myopia was
calculated as (39/9243) × (877/815) = 0.45%.
The second population group studied by Goldschmidt5
consisted of Danish military conscripts. However, instead
of quoting the prevalence of high myopia for this
population, he reported the prevalence of myopia >−6.50
D. Thus, to enable comparison with this latter group, we
have calculated the prevalence of myopia >−6.50 D for the
boys in Goldschmidt’s population of 9243 children. Mak-
ing the assumption that 50% of the children were male, the
prevalence was (2 × 12/9243) × (877/815) = 0.28%. This
assumption seems valid since Goldschmidt reported that
exactly 50% of the 8981 children attending “normal”
schools were male.
We calculated the heritability of high myopia from the
family data for highly myopic children identified by
Goldschmidt,5 using the method described by Falconer31
and Vogel and Motulsky,32 where heritability is defined as
the ratio of additive genetic variance (VA) to phenotypic
variance (VP). Briefly, midparent-oVspring heritability was
calculated as h = (r/0.5) where r was the correlation
between midparent versus oVspring ocular refractions. As
suggested,31 oVspring data were averaged for each family
analysed. Sib-sib heritability was calculated as h2 = 2r
where r was the correlation between probands and the
mean of the other sibs. Probands were included in the
analysis since they were derived from a sample which was
considered unselected. The 95% confidence intervals of
the correlation were calculated and the null hypothesis of
zero correlation was tested, as described by Altman.33 To
avoid a source of potential bias, right and left eyes were
analysed independently, since ocular refractions were
highly correlated between the two eyes of subjects.5
The risk ratio for sibs (ës) for high myopia was calculated
for Goldschmidt’s child population according to the
formula ës = risk to sibs of aVected probands/population
prevalence, as described.34 The population prevalence of
high myopia for this group of children was taken as 0.45%.
It was not possible to calculate a risk ratio for sibs (ës) for
low myopia from Goldschmidt’s study group because fam-
ily data were only available for the highly myopic children.
In fact the only previous study that reported suYcient data
to enable such a calculation was that of Sperduto et al.35
This contained refractive data for a representative cross
section of North American families. Unfortunately,
however, the population group studied by Sperduto et al35
was separated both in time (one and a half generations) and
geography (Denmark versus the United States) from the
population studied by Goldschmidt.5 The population
prevalence of myopia in the sample of Sperduto et al35 aver-
aged 35%; however, it varied with both age and sex (range
18-68%). Furthermore, this population also contained
Table 2 Heritability estimates for myopia from twin studies
Study Heritability No of twin pairs Age Calculation Comments
Sorsby et al50 h2 = 0.87 MZ = 78 4–14
h2 =
rmz - rdz Calculation of heritability by Goss et al
21
DZ = 40 (ls) 1 - rdz
Nakajima51 h2 = 0.83 MZ = 39 12–17
h2 =
ÄDZ - ÄMZ Same subject group and calculation in 2 studies. Only used
part of sample for analysisNakajima et al46 h2 = 0.73 DZ = 10 (ls) ÄDZ
Kimura52 h2 = 0.80 MZ = 33 15–20
h2 =
ÄDZ - ÄMZ
DZ = 16 (nls) ÄDZ
Hu53 h2 = 0.61 MZ = 49 7–19
h2 =
rmz - rdz
DZ = 37 (nls) 1 - rdz
Lin and Chen54 h2 = 0.25 MZ = 90 7–23 h2 = 2(rMZ - rDZ)
DZ = 36 (ls)
Teikari et al55 h2 = 0.58 MZ = 54 30–31 h2 = 2(rMZ - rDZ)
DZ = 55 (ls)
Angi et al56 h2 = 0.11 MZ = 19 3–7 h2 = 2(rMZ - rDZ) Unusually high prevalence of form deprivation myopia
DZ = 20 (ls)
h2 = heritability, MZ = monozygotic, DZ = dizygotic, ls = like sexed, nls = non-like sexed, rmz = correlation coeYcient of MZ twins, rdz = correlation coeYcient of DZ
twins, rMZ = intrapair correlation coeYcient in MZ twins (correlation in liability), rDZ = intrapair correlation coeYcient in DZ twins, ÄDZ and ÄMZ not defined by the
authors.
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high myopes and we were not able to exclude these from
the analysis. Fortunately, the high myopes were vastly out-
numbered by low myopes and thus were unlikely to aVect
the magnitude of the risk ratio for low myopia that was
obtained. Because of the mode in which results were
presented by Sperduto et al,35 risk to sibs was inferred from
families containing only two sibs, in which both, one, or
neither of the sibs were aVected by myopia. There were 255
such families (510 sibs) and the prevalence of myopia in
this group was 39% (198 of the 510 sibs). With 57 families
having two myopic sibs, the risk ratio for sibs (ës) for low
myopia was therefore ≈1.5.
Results. Goldschmidt5 screened the medical records of
95% of the children born in Copenhagen in the year 1948
and found that 9.5% of the children sampled were myopic.
He then examined 93% of the myopic children in person to
determine their precise ocular refraction (the children
being aged 13-14 at the time of the survey). Thirty-nine
children were classified by Goldschmidt as high myopes
giving a prevalence of 0.45%. Family data were available
for 36 of these 39 subjects. Of the three families for which
data were not reported, one family did not want to cooper-
ate with the investigation, while in the other two the
probands lived in foster homes. Refractive data for one of
the parents was not available for five of the 36 families,
leaving 31 “complete” families available for reanalysis.
We calculated the midparent-oVspring heritability esti-
mates for ocular refraction in the 31 complete families to
be 0.65 and 0.68 for right and left eyes, respectively (both
significantly above zero at the p<0.01 level). In contrast,
the sib-sib heritabilities for the 36 incomplete families
described by Goldschmidt5 were not significantly diVerent
from zero (h2 = −0.09 and +0.12 for right and left eyes,
respectively). No improvement was gained by restricting
the sib-sib analysis to just those sibs from the 31 complete
families. The midparent-oVspring heritability estimates
calculated here for the families of Goldschmidt’s highly
myopic probands are higher than those found previously
(for unselected families, table 1), while the sib-sib
heritability estimates for this sample are much lower than
has been found previously (table 1).
The risk ratio for sibs (ës) for high myopia, calculated
from Goldschmidt’s data, is 20.0 (four sibs out of a total of
44 were highly myopic). Furthermore, if only sibs older
than the probands are considered, the risk ratio is even
higher (ës=27.5, since three out of 24 older sibs were
aVected), suggesting that the inclusion of sibs who have yet
to develop high myopia leads to the risk ratio being under-
estimated.
The study by Sperduto et al35 is the only one containing
suYcient detail to enable a risk ratio for low myopia to be
calculated. This study yields a ës≈1.5 for low myopia.
Importantly, because the population prevalence of myopia
in the unselected sample studied by Sperduto et al35
averaged 35%, the risk ratio could never have exceeded the
theoretical maximum of 2.9 (numerator in ës equation
must be <1, denominator = 0.35).
Discussion. Several factors limit the reliability of the her-
itabilities and risk ratios reported here. Consequently,
these results should be interpreted with caution and
considered only as estimates. Some of the more important
limiting factors are discussed below.
Results from an older Danish population group
described in Goldschmidt’s 1968 paper5 suggest that many
of the children he sampled had yet to develop myopia. In
18-20 year old Danish military conscripts, the prevalence
of myopia was 14.5%, whereas it was only 8.5% in the
13-14 year old boys. Furthermore, while 0.6% of his con-
script sample had myopia >−6.50 D, only 0.3% of the male
children had this degree of myopia. Thus, it seems very
likely that some children who would eventually become
high myopes were not followed up in Goldschmidt’s analy-
sis of parents and sibs. This eVect of sampling a population
group at an age before myopia has stabilised is likely to
have led to the sib-sib heritability being underestimated,
since heritability calculations use a correlation approach
that relies on an analysis of quantitative data. Also, since
ocular refraction continues to vary with age,6 35 parent-
oVspring heritability estimates might also be aVected. Risk
ratio estimates, in contrast, are based on an all or nothing
approach, the presence or absence of a trait. Thus, risk
ratios may be less susceptible to problems caused by age
related variations in refraction than heritabilities.
Despite the large population targeted by Goldschmidt,5
only 36 highly myopic probands and their families were
available for analysis. The use of such a small sample will
inevitably have led to inaccuracy in both heritability and
risk ratio estimations.
It could be argued that the ës values for high and low
myopia reported here are not strictly comparable, since
they relate to population groups that not only derive from
diVerent geographical areas, but that are one and a half
generations apart. However, since the population preva-
lence of myopia in Goldschmidt’s population sample was at
least 15%, the ës for low myopia for this group could not
have exceeded the theoretical maximum of 6.7 (1 divided
by 0.15) and therefore would still be much less than that of
high myopia.
The heritability estimates derived here from midparent-
oVspring and sib-sib analyses suggest that genetic factors
might contribute to the determination of ocular refraction
diVerently in highly myopic members of the population
compared to the general population. However, it is unclear
why the sib-sib heritability in the present sample should be
so low, especially since sib-sib heritability has usually been
thought to overestimate the role of additive gene eVects in
determining ocular refraction.13 31 Falconer31 suggested that
midparent-oVspring heritability is likely to be the most
reliable heritability indicator in human populations.
According to this postulate, our results can be interpreted
as suggesting that genetic factors exert a greater eVect in
determining high myopia than low myopia.
Significantly, the high risk ratio for sibs (ës) for high
myopia found here also suggests an important role for
heredity in determining extremes in ocular refraction. Fur-
thermore, our data are consistent with the idea that high
myopia is more likely to be determined by familial factors
than is low myopia.
Very recently, Young et al29 30 described two discrete loci
for simple high myopia in pedigrees showing an apparently
autosomal dominant pattern of inheritance. Interestingly,
in three of the four families in which Goldschmidt’s highly
myopic probands had an aVected sib, one or more of the
parents was also aVected. Moreover, in the nine families
that had at least one aVected parent, 50% of sibs were
aVected. Both of these results are suggestive of a dominant
pattern of inheritance, and so dominant genes may be
responsible in large part for the high ës for high myopia.
However, since this dominant transmission pattern was
only evident in nine of the 36 families in Goldschmidt’s
cohort, it seems likely that other modes of inheritance of
high myopia are more common than dominant inheritance.
The failure to identify a major dominant myopia gene by
segregation analysis36 is consistent with this view, although
a recent study of the inheritance of corneal astigmatism37
suggests that this type of segregation analysis is not always
capable of disclosing dominant gene eVects.
The frequency distribution of ocular refraction is
leptokurtotic rather than normal, and skewed towards
myopia.4 38–40 However, a reanalysis of Goldschmidt’s sam-
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ple of 815 children shows that for this population, the fre-
quency distribution of the number of myopic eyes can be
described as a single inverse exponential function, except
for myopia >−9.00 D (fig 1). It is tempting to speculate
that this bimodal (or multimodal) distribution reflects two
or more aetiologically distinct types of myopia. Betsch,39
Scheerer,40 Tron,42 and Hirsch43 all reached similar conclu-
sions, albeit with a variety of optimal “cut oV” levels at
which point the bi- or multimodality became evident.
However, none of these authors based their analyses on an
unselected population group such as that provided by
Goldschmidt. The diVerences in heritability and risk ratio
between high and low myopia are consistent with this idea
of aetiological bimodality, although this is clearly an
oversimplification.43 44
The risk ratio for sibs for high myopia was approximately
20, compared to ≈1.5 for low myopia. In addition, the
midparent-oVspring and sib-sib heritabilities for the fami-
lies of Goldschmidt’s high myope population diVered from
those reported for unselected families. Finally, it was noted
that the frequency distribution of myopia in Goldschmidt’s
unselected child population group conformed well to a
biphasic distribution, consistent with the occurrence of two
aetiologically distinct, major forms of myopia. Taken
together, these results suggest that genetic factors play a
significant role in the development of high myopia.
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Progressive neurological deterioration
in a child with distal arthrogryposis
and whistling face
EDITOR—Freeman-Sheldon syndrome (FSS) (McKusick
193700), described in 1938, is characterised by a whistling
face with a long philtrum, a puckered mouth, microstomia,
H shaped cutaneous dimpling on the chin, multiple joint
contractures with camptodactyly, ulnar deviation of the
fingers, bilateral talipes equinovarus, and kyphoscoliosis.1
Burian rediscovered the entity and called it the “whistling
face syndrome”.2 There is genetic heterogeneity.3–6 Both
autosomal dominant7 8 and recessive inheritance9–12 have
been described.
The psychomotor development of aVected children is
usually normal in the autosomal dominant forms,6 13 14
although mild motor delay attributable to joint anomalies
has been reported occasionally.3 15–18 A few patients with
severe developmental retardation have been described, all
with autosomal recessive inheritance.19–22
We describe a child who presented from birth with distal
arthrogryposis, profound mental retardation, severe hypo-
tonia, and whistling face. The severe neurological involve-
ment precludes him from having FSS according to the
classification of Bamshad et al.23 We suggest that patients
with a whistling face, distal contractures, and severe
neurological involvement should be diagnosed as having a
separate autosomal recessive syndrome.
The patient was the first child of non-consanguineous,
healthy, Moroccan Jews. The pregnancy was attained by in
vitro fertilisation and was unremarkable. He was born at 42
weeks’ gestation. Apgar scores were 4 at one minute and 6
at five minutes; pH was 7.11 and improved with
bicarbonate infusion. A single seizure on the second day
did not recur following phenobarbital therapy. Hypotonia
with scarce spontaneous movements but increased reflexes
was first noticed then. Length, weight, and head circumfer-
ences were on the 50th centile.
He was first evaluated at the age of 6 months when his
weight had dropped below the 5th centile. Physical exam-
ination showed a puckered mouth, mild retrognathia,
camptodactyly of fingers 2 and 3, adducted thumbs, and
rocker bottom feet (fig 1). Brain CT and MRI scans, EEG,
echocardiogram, karyotype, and muscle biopsy including
electron microscopy were normal. A diagnosis of the fetal
hypokinesia sequence was considered at that time. A meta-
bolic evaluation, including blood lactic, pyruvic, amino,
phytanic, and very long chain fatty acids and urinary
organic and bile acids, was normal.
At the age of 36 months clinical examination showed
whistling face, micrognathia, a small mouth with a long
philtrum and downturned upper lip, blepharophimosis,
prominent and narrow forehead, and bitemporal balding.
Height was on the 20th centile, head circumference was on
the 2nd centile, and weight was on the 50th centile for 12
months (−3 SD for his age). He was very thin, with an
expressionless face and bilateral hand contractures with
camptodactyly and ulnar deviation. His chest was flat with
decreased anterior-posterior diameter (fig 2). Limb move-
ments were scarce and there was no head control. He was
able to follow with his eyes but could not smile. Eye exam-
ination was normal. Bronchoscopy showed severe laryngo-
malacia. There were frequent desaturations with CO2
Figure 1 The patient in the neonatal period with puckered mouth and H shaped cutaneous dimpling of the chin.
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retention. The muscles were atrophic but reflexes were
increased. There has been no neurological development
since birth.
A repeat brain MRI showed generalised cerebral,
cerebellar, and brain stem atrophy (fig 3). Further evalua-
tion including isoelectric focusing of transferrins and spec-
tral karyotyping of his chromosomes was normal.
Freeman-Sheldon syndrome (FSS) was classified among
the congenital arthrogryposis syndromes assuming a
possible myopathic origin of both facial anomalies and
joint contractures.14 However, EMG and structural abnor-
malities have not always been detected in the muscles
involved.14 24–26 In addition, the most frequently described
muscle abnormality, substitution of muscle tissue with
connective tissue, may be a consequence rather than a
cause of joint immobility.3
Congenital arthrogryposis is part of the fetal akinesia
sequence. There are multiple pathogenic factors involved
in fetal hypokinesia, such as central nervous system
malformations, spinal cord disease, neuromuscular disor-
ders, and a restricted fetal environment.20 There are also
numerous syndromes that present with this sequence. In
the Marden-Walker and Pena-Shokeir syndromes the
cause of the akinesia is unclear. Bamshad et al23 recently
included FSS as one of the distal arthrogryposes and des-
ignated it DA2. Their definition of a distal arthrogryposis is
“an inherited primary limb malformation disorder charac-
terised by congenital contractures of two or more diVerent
body areas and without primary neurologic and/or muscle
disease that aVects limb function”. Indeed in most of the
reported cases intelligence was described as normal; this
includes all cases with autosomal dominant
inheritance6 13 14 and some of the cases with autosomal
recessive inheritance.12
Recently, a variant of FSS with dominant inheritance has
been mapped to chromosome 11p15.5-pter.4 A small
group of patients with severe central nervous system
involvement and presumed autosomal recessive inherit-
ance has been described (table 1).
Illum et al19 reported two sisters and a brother from a
sibship of four who were born with multiple joint contrac-
tures, camptodactyly, an expressionless face with a
puckered mouth, and restricted mouth opening. There
were widespread calcium deposits in the leptomeninges, on
the surface of the cerebral convolutions, and throughout
the brain. Calcification was also found in skeletal muscles.9
Schrander-Stumpel et al,20 Di Rocco et al,21 Zampino et al,22
and Hageman et al27 reported other similar cases.
Schrander-Stumpel et al20 reported three unrelated patients
who had distal arthrogryposis, severe developmental retar-
dation, and a “whistling face” associated with the
Pierre-Robin sequence. Zampino et al22 described a
sporadic case of the whistling face syndrome in a boy who
also had severe hypertonia, swallowing problems, poor
weight gain, and cerebellar and brain stem atrophy. They
suggested that primary brain anomalies may explain many
of the syndrome’s manifestations. They suggested it might
be more appropriate to speak of the Freeman-Sheldon
Figure 2 The patient at the age of 3 years. Note the whistling face, long
philtrum, blepharophimosis, narrow forehead, extreme failure to thrive, flat
chest, camptodactyly, and adducted thumbs.
Figure 3 MRI at the age of 3 years. T1 weighted coronal image.
Prominent cerebral and cerebellar atrophy.
Table 1 Comparison of the present patient to those previously reported
Clinical symptoms Illum et al19 Schrander-Stumpel et al20 Di Rocco et al21 Zampino et al22 Present patient
Polyhydramnios 2/3 3/3 − − −
Postnatal growth retardation 1/1 2/3 Died 6 mth + +
Hypotonia 3/3 3/3 + − +
Distal contractures 3/3 3/3 + + +
Whistling face 3/3 3/3 + + +
High palate 1/3 − + + +
Seizures 2/3 3/3 + − Single
Severe mental retardation 1/1 3/3 + + +
Early death 3/3 1/3 At 6 mth At 5 mth
Neuroimaging abnormalities 2/3 + +
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spectrum rather than syndrome because of the diVerent
pathogenic mechanisms (muscular, skeletal, and neuro-
logical), the wide range of clinical manifestations, and the
genetic heterogeneity.
Our patient manifests characteristic features of whistling
face with profound mental retardation and central hypoto-
nia (normal muscle biopsy). An MRI obtained at the age of
6 months was normal, but a repeat study at the age of 3
years showed progressive cerebral, cerebellar, and brain
stem atrophy (fig 3). Schrander-Stumpel et al20 described a
slightly enlarged cisterna magna and interhemispheric fis-
sure in one patient and ventricular enlargement in the
other, and Zampino et al22 found atrophy of the brain stem
and the cerebellum, both on CT scans.
We suggest that there may be several distinct genetic
syndromes with whistling face and distal contractures, one
autosomal dominant with no neurological involvement, fit-
ting the definition of the distal arthrogryposes and
designated DA2, and the others possibly autosomal reces-
sive with variable central nervous system involvement. The
syndromes with normal intelligence may be caused by a
primary abnormality of tendon growth and development,23
while the others may be attributed to a primary or second-
ary brain anomaly as suggested by several authors.19–22 The
progressive atrophy seen on our patient’s MRI may suggest
that features of whistling face with severe neurological
involvement may not be the result of a primary brain mal-
formation but rather an as yet unknown metabolic neuro-
degenerative disorder, starting in utero and causing fetal
hypokinesia and prominent hypotonia from birth. The lack
of any developmental milestones, the acquired micro-
cephaly, failure to thrive, and early death are manifestations
of the postnatal downhill course in this disorder. The early
death seen in most of the patients (table 1) may be attrib-
uted to brain stem involvement with progressive feeding
and respiratory diYculties. Our patient underwent an
extensive metabolic evaluation. We have ruled out organic
and amino acidurias, peroxisomal and mitochondrial
disorders, and recently also disorders of glycoconjugates,
which have been implicated in patients with developmental
delay and cerebellar atrophy.28 Deficiency of a factor
important in both pre- and postnatal brain development
may be the primary abnormality in this syndrome. More
cases are needed to understand and delineate this
syndrome further and to facilitate mapping.
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Chromosomal duplication of band
10p14 segregating through four
generations
EDITOR—In recent years the increased resolution that can
be obtained with GTL banded prometaphase chromo-
somes has led to the recognition of abnormalities involving
small regions of the karyotype. Some of these abnormali-
ties involve deletion or duplication of only one or two
chromosomal bands and are associated with a suYciently
mild phenotype as to be directly inherited. Nevertheless,
directly inherited duplication of visible chromosomal
material is an uncommon category of chromosomal
abnormality that has been reported for a small number of
specific regions of the karyotype, including 2q11.2-q21.1,1
6p23-pter,2 6q22-q24,3 7p12-p13,4 8p23.1,5 9p22-p24,6
14q13-q22,7 15q12,8 and 18p.9 Some of these duplications
are without apparent phenotypic eVect,5 8 while in other
cases there are mild phenotypic abnormalities.1 2 Genomic
imprinting has been shown to have an eVect on the
phenotypic expression of dup(15)(q12)8 and also
dup(6)(q24),3 and is a point for consideration in other
small duplications.
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Tandem duplications occur when a second copy of a
chromosomal region is inserted adjacent to the original
region. They have been reported for a number of chromo-
somal segments,2 9 although not previously for band
10p14. Microduplication and microdeletion of chromo-
somal material is presumed to occur as a meiotic event fol-
lowing uneven crossing over between short sequences of
highly similar DNA inserted at two close, but not contigu-
ous sites along the chromosome.10 11 Tandem duplication is
generally de novo with rare cases reported of direct
inheritance.3–6 8 9 To be balanced, an intrachromosomal
duplication would have to be associated with chromosomal
deletion of the specific region in the other homologue and
to have occurred postzygotically. To our knowledge, this
type of balanced chromosomal rearrangement has not been
reported as a constitutional abnormality. We describe here
a previously unreported small chromosomal duplication of
band 10p14 segregating in a large pedigree with apparently
direct inheritance in at least eight subjects, three of whom
presented independently as index cases.
The pedigree of the family is shown in fig 1, with the
three probands indicated. Proband 1 (IV.9 in fig 1, fig 2)
was referred for chromosome studies at the age of 1 year 9
months with the clinical indications of intrauterine growth
retardation, mild developmental delay, and small testes. A
cleft palate had since been repaired. The child was in fos-
ter care and the foster parents reported the biological par-
ents to be intellectually handicapped and the mother to
have a very aggressive personality. There are two female
sibs, both of whom are regarded as being intellectually
normal, although neither has been seen by us. On review at
2 years 8 months, the child was small with height 88 cm
(approximately 5th centile), weight 11 kg (3rd centile), and
head circumference 47.7 cm (2 cm >3rd centile). He was
being treated for seizures. He had no speech and no real
vocalisation. Facial dysmorphism was definite but not
marked, with the particular observations of a periorbital
fullness, a flat nasal bridge with inner canthal folds, and a
flattish midface (fig 2). The testes were abnormally small.
There were bridged palmar creases on both hands and a
degree of proximal implantation of the fourth toe on the
right. Joint hypermobility was noted at the ankles.
Proband 2 (IV.5, fig 1) was referred with developmental
delay. On review at the age of 2 years 2 months, he had no
speech and displayed hyperactive aggressive behaviour.
There was no definite facial dysmorphism. His father
(III.6) had an essentially normal facies and habitus, other
than an upper spinal kyphosis. He could converse sensibly,
intelligibly, and appropriately. He had had special school-
ing and had previously worked in a sheltered workshop,
although at the time of interview he was in normal
employment as a forklift driver. He was prone to anger,
which he himself recognised as a problem. He expressed
aVection and concern for his son, having an insight into the
diYculties that the chromosome abnormality had caused.
However, he has since left the family, and the three children
(IV.5-7) are now being brought up by their retarded
mother and normal maternal grandparents.
Proband 3 (III.4, fig 3) was referred for chromosome
analysis with the indications of intellectual impairment and
short stature at the age of 14 years. On clinical examination
at the age of 16, he was borderline microcephalic (head
circumference 52.7 cm, 2nd centile). He had deep set eyes,
a high nasal bridge with a broad nasal tip, flat midface,
large mouth, and low set ears (fig 3). He had hypermobile
joints. He would not allow examination of his genitalia. He
was in special schooling and exhibited “boisterous” behav-
iour. His mother (II.2) had borderline mental abilities and
had facial features similar to her son’s (fig 3B). She had a
nerve deafness. She reported her daughter III.1 to be men-
tally retarded. One grandchild (IV.4) is said by II.2 to be
developmentally delayed, but neither he nor his mother
(III.2) was available for study.
Metaphase cells were prepared for chromosome analysis
from peripheral blood samples using standard techniques.
Cells were synchronised using either excess thymidine or
FudR with BrdU release. Chromosome analysis of the three
probands showed in each an apparent duplication of band
Figure 1 Family pedigree. Subjects with the 10p duplication are shown as filled symbols, obligate heterozygotes as grey symbols, and subjects with mental
defect of unknown cause who have not yet been cytogenetically studied are shown quarter filled. III.5, IV.6, and IV.7 have normal karyotypes. We
understand III.7, IV.8, and IV.10 to be of normal intelligence.
I
II
III
IV N N
N
1 2
1 2
1 2
21 3 4 5 6 7 8 9 10
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10p14 (46,XY,dup(10)(p13p15)) (fig 4A, B, D). Chromo-
some studies on the parents of proband 2 had initially been
interpreted to show mosaicism for the dup(10)(p14) in the
father (III.6). Given the structure of the pedigree, as it sub-
sequently came to light, and upon review of the cytogenetic
material, his karyotype was reinterpreted as non-mosaic
46,XY,dup(10)(p13p15) (fig 4C). The duplication of band
10p14 could be observed in chromosomes around the 850
band level. In shorter chromosomes at 400-500 band levels,
the duplication is observed as a more intense band than the
normal 10p14 band present in the homologue, making it
diYcult to distinguish the duplication from banding
variation. Chromosome studies on the mother of proband 3
also showed dup(10)(p13p15) (fig 4E). Her daughter had
been referred for cytogenetic study in 1987 and a normal
karyotype was reported at that time, but upon review of the
archived slides her karyotype was reinterpreted as
46,XX,dup(10)(p13p15)mat. Chromosome painting was
carried out using a chromosome 10 specific paint (Cambio,
Cambridge, UK). Chromosome painting (fig 5) of meta-
phase cells from proband 1 (IV.9) using a chromosome 10
specific paint showed uniform hybridisation over both
chromosomes 10 (with the exception of the heterochro-
matic pericentromeric region). This indicated that the rear-
rangement in the distal region of 10p was not the result of
either interchromosomal insertion or translocation.
Probes previously mapped to 10p14 (JC2080) and
10p15 (JC2216) (obtained from Dr Jen-I Mao)12 were
labelled with either biotin or digoxigenin by nick
translation following the manufacturer’s recommended
method. Fluorescence in situ hybridisation (fig 6) on meta-
phase chromosomes from proband 3 (III.4) using probe
JC2216 (10p15) showed hybridisation of comparable
intensity to the terminal region of both the normal and
duplicated chromosomes 10. In comparison, hybridisation
with the probe JC2080 showed hybridisation to band
10p14 with increased intensity of signal present on the
duplicated chromosome compared with the normal
chromosome.
Comparative genomic hybridisation was performed
using a modified protocol13 of the procedure described by
Kallioniemi et al.14 Genomic DNA was extracted using the
nucleon kit (Amersham) according to the manufacturer’s
instructions and directly labelled by nick translation using
a Vysis kit according to the manufacturer’s instructions.
Test DNA was labelled with green fluorochrome and nor-
mal reference DNA was labelled with red fluorochrome.
DNA samples obtained from proband 1 (IV.9) and from
proband 2 (IV.5) were used in CGH experiments. For both
samples, deviation of the profile towards the right occurred
in the region of 10p14, indicating extra copies of DNA
sequence in the test samples for this region (fig 7A).
Thus, we have described a chromosomal duplication of
the band 10p14 that was ascertained independently during
routine clinical cytogenetic analysis of GTL banded
prometaphase chromosomes in three subjects, referred
Figure 2 IV.9 aged 2 years 8 months showing minor dysmorphism. Note the periorbital fullness, anteverted nares, and midfacial flatness with relative
prognathism.
Figure 3 II.2 and III.4 at ages 16 and 47, respectively, showing only subtle dysmorphism. The clearest observation is of maxillary flatness.
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because of mental retardation. In two cases the abnormal-
ity was shown by cytogenetic studies to be directly
inherited from a parent who also showed similar clinical
features to those seen in the child. Review of the genetic
files of the three probands showed that they all belonged to
a single kindred (fig 1). Although some family members
interviewed were aware of mental retardation and behav-
ioural problems elsewhere in the family, they did not know
of the chromosome abnormality. There had been consider-
able family dysfunction, and some of the presumed
unaVected family members have been at pains to avoid
contact with their relatives.
Chromosome painting indicated that the abnormality in
the distal region of 10p involved only chromosome 10
material, with neither insertion nor translocation of
chromosomal material from another chromosome. CGH
studies on DNA from two of the probands showed that
there was increased copy number for the DNA in the distal
region of 10p. This confirmed the interpretation made on
the basis of the GTL banding of prometaphase chromo-
somes, namely, that the chromosome rearrangement is a
tandem duplication of band 10p14 with breakpoints in
10p13 and 10p15. FISH studies using probes mapped to
bands 10p15 and 10p14 were confirmatory.
In terms of dysmorphology, the phenotype associated
with this karyotype is mild, shading into apparent
normality in case III.6. Hyperactive, impulsive, and
intemperate behaviour is common and cognitive impair-
ment is universal. A number of examples of 10p trisomy
are on record,15 but to our knowledge only two show
duplication for a very similar region. Stone et al16
described dup(10p14→10pter) in a father and two
daughters, and Benzacken et al15 reported dup(10)
(p14→pter) resulting from a de novo unbalanced translo-
cation. This is a larger region than the duplicated segment
in the present kindred, but there is some phenotypic over-
lap. All have had mental defect. In respect of physical
attributes, midfacial hypoplasia, epicanthic folds, and
anteverted nares are in common in our cases and in those
of Stone et al.16 Optic nerve defects, subtle or major, were
described in the three aVected subjects in the family of
Stone et al16 and agenesis of the corpus callosum was
shown in the patient of Benzacken et al.15 These defects
have not been specifically sought in our cases.
The presumed parent in generation I who has apparently
transmitted the duplication to at least two oVspring (II.2
and, inferentially, II.5) may have been a non-mosaic carrier
of the duplication, although given family reports that I.1
and I.2 were both of normal intelligence, the possibility of
mosaicism remains an open question. All other obligate
carriers in this kindred must have duplication of 10p14 in
non-mosaic state, inherited by direct transmission. Segre-
gation of the duplication from a parent to an aVected oV-
spring is proven in 8/21 meiotic segregations, with at least
two segregations uncertain. There is no obvious selection
against the duplication, and the segregation pattern is
comparable to that of an autosomal dominant condition.
This suggests that the duplication does not interfere with
meiotic pairing and segregation, and that in utero viability
is little, if at all, compromised. Fertility is apparently not
aVected, albeit there is the observation of small testes in
one child at the age of 2 years 8 months. The duplication
has been transmitted both maternally and paternally, with
no clear distinction of phenotypic patterns in the two
classes of aVected oVspring, arguing against an imprinting
eVect. While direct transmission of chromosomal duplica-
tions (and deletions) is well described, this is the first
report of a cytogenetically detectable chromosome dupli-
cation associated with phenotypic abnormality segregating
Figure 4 GTL banded partial karyotypes showing the normal chromosome 10 and the duplicated chromosome 10 (on the right) from (A) IV.9, (B) IV.5,
(C) III.6, (D) III.4, (E) II.2, and (F) III.1.
A B C
D E F
Figure 5 Chromosome painting using a chromosome 10 specific paint
showing uniform hybridisation to both the normal and duplicated
chromosomes 10.
236 Letters
 group.bmj.com on April 22, 2010 - Published by jmg.bmj.comDownloaded from 
through as many as four generations of one family. This
genetic abnormality has been the cause of an extraordinary
amount of inherited mental deficiency and psychopathol-
ogy in the family.
Patients III.6 and IV.5 were referred by Dr I J Skelton, patient III.4 by
Dr S Anderson, and patient IV.9 by Dr H Zehnwirth.
LUCILLE VOULLAIRE
R J MCKINLAY GARDNER
CATHRYN VAUX
ANNE ROBERTSON
RALPH OERTEL
HOWARD SLATER
Victorian Clinical Genetic Services, The Murdoch Institute, Royal
Children’s Hospital, Flemington Road, Parkville, Victoria 3052, Australia
Correspondence to: Dr Voullaire
1 Glass IA, Stormer P, Oei PTSP, Hacking E, Cotter PD. Trisomy
2q11.2→q21.1 resulting from an unbalanced insertion in two generations.
J Med Genet 1999;35:319-22.
2 Delatycki MB, Voullaire L, Francis D, et al. Directly inherited partial
trisomy of chromosome 6p identified in a father and daughter by chromo-
some microdissection. J Med Genet 1999;36:335-8.
3 Gardner RJ, Mungall AJ, Dunham I, et al. Localisation of gene for transient
neonatal diabetes mellitus to an 18.72 cR3000 (∼5.4 Mb) interval on
chromosome 6q. J Med Genet 1999;36:192-6.
4 Schaefer GB, Novak K, Steele D, et al. Familial inverted duplication 7p. Am
J Med Genet 1995;56:184-7.
5 Barber JCK, Joyce CA, Collinson MN, et al. Duplication of 8p23.1: a cyto-
genetic anomaly with no established clinical significance. J Med Genet
1998;35:491-6.
6 Haddad BR, Lin AE, Wyandt H, Milunsky A. Molecular cytogenetic char-
acterisation of the first familial case of partial 9p duplication (p22p24). J
Med Genet 1996;33:1045-7.
7 Pot MLH, Giltay JC, van Wilsen A, Breslau-Siderius EJ. Unbalanced karyo-
type, dup 14(q13-q22), in a mother and her two children. Clin Genet 1996;
50:398-402.
8 Cook EH, Lindgren V, Leventhal BL, et al. Autism or atypical autism in
maternally but not paternally derived proximal 15q duplication. Am J Hum
Genet 1997;60:928-34.
9 WolV DJ, RaVel LJ, Ferré MM, Schwartz S. Prenatal ascertainment of an
inherited dup(18p) associated with an apparently normal phenotype. Am J
Med Genet 1991;41:319-21.
10 Mazzarella R, Schlessinger D. Pathological consequences of sequence dupli-
cations in the human genome. Genome Res 1998;8:1007-21.
11 Lupski JR. Genomic disorders: structural features of the genome can lead to
DNA rearrangements and human disease traits. Trends Genet 1998;14:417-
22.
12 Zheng CJ, Ma NSF, Dorman TE, et al. Development of 124 sequence-
tagged sites and cytogenetic localization of 217 cosmids for human
chromosome 10. Genomics 1994;22:55-67.
13 Voullaire L, Wilton L, Slater H, Williamson R. Detection of aneuploidy in
single cells using comparative genomic hybridization. Prenat Diagn
1999;19:846–51.
14 Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative
genomic hybridization for analysis of DNA sequence copy number changes
in solid tumours. Genes Chrom Cancer 1994;10:231-43.
15 Benzacken B, Lapierre JM, SiVroi JP, Chalvon A, Tachdjian G.
Identification and characterization of a de novo partial trisomy 10p by com-
parative genomic hybridization (CGH). Clin Genet 1998;54:334-40.
16 Stone D, Ning Y, Guan XY, Kaiser-Kupfer M, Wynshaw-Boris A, Biesecker
L. Characterization of familial partial 10p trisomy by chromosomal micro-
dissection, FISH, and microsatellite dosage analysis. Hum Genet 1996;98:
396-402.
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Somatic mosaicism associated with a
mild Alport syndrome phenotype
EDITOR—Alport syndrome (AS) is a hereditary nephritis
characterised by haematuria, proteinuria, and chronic
renal failure associated with progressive high tone
sensorineural deafness and characteristic eye lesions
(macular flecks and anterior lenticonus1). At the molecular
level, X linked AS, which is the most common form, is
caused by mutations in COL4A5, a type IV collagen gene
expressed in the glomerular basement membrane of the
kidney.2 Mutations in COL4A5 cause progressive kidney
damage usually leading to renal failure in aVected males in
early adulthood (20-25 years, juvenile form). A small pro-
portion of COL4A5 mutations cause a later onset form of
AS with ESRF in males at >31 years, although nephritis is
apparent much earlier than this. Heterozygous females are
generally mildly aVected and often do not develop renal
failure. We report here the identification of three
apparently mosaic parents (two mothers and one father) of
aVected subjects. In the case of the mosaic father, an unu-
sually mild AS phenotype was observed which may be a
consequence of his mosaicism.
The COL4A5 gene is composed of 51 exons spread over
250 kb of genomic DNA, which generate a 6.5 kb
transcript encoding a 1685 amino acid protein3 and has
been the subject of several large mutation studies.4–6 We
have recently completed a screen of all 51 exons of
COL4A5 in 153 patients with suspected X linked AS using
single strand conformation polymorphism (SSCP) analysis
followed by direct sequencing of fragments showing
mobility shifts, and have identified mutations in 77 of these
families.7 Where samples were available, other family
members were analysed by SSCP both to provide accurate
carrier diagnosis and to estimate the proportion of de novo
mutations. In total, the mothers of 25 aVected males and
both parents of three aVected females were screened,
showing five de novo mutations and three instances of
mosaicism.
In patient 15, AS is caused by a mutation in exon 26,
2208G→C, which changes glycine 669 to alanine and
interrupts the Gly-X-Y repeat structure of the collagen tri-
ple helix.7 The proband is an 11 year old male who
presented with haematuria at 9 years, but has no reported
deafness or eye lesions and has not yet developed renal
failure. His mother, who also has haematuria but no other
signs, was found by SSCP analysis to possess a reduced
amount of the mutant allele and this was confirmed using
DNA extracted from a second blood sample (fig 1A). As an
additional control, an equimolar mixture of DNA from her
son and an unrelated, unaVected male was analysed to
show that the two alleles amplified equally (data not
shown). DNA from both maternal grandparents has also
been analysed and neither possesses the mutation (fig 1A).
On the basis of these results we can be unequivocal that the
mutation causing AS in this family arose somatically in the
mother.
A splice site mutation (849-3c→a), which results in the
in frame skipping of exon 12, causes AS in patient 47.8 This
man was diagnosed with haematuria and a renal biopsy
showed irregular thickening and splitting of the glomerular
basement membrane typical of AS before he developed end
stage renal failure at the age of 17 years. He shows no loss
of hearing or characteristic eye signs. His mother (who
Figure 1 Somatic mosaicism in AS. Mosaicism is shown by SSCP
analysis in (A) the mother of patient 15 using oligonucleotides flanking
exon 26 (taccattgatttactcttgc and aataaattcctcacatac) and (B) the mother
of patient 47 using oligonucleotides flanking exons 11 and 12
(ttgtcttctcttcttagg and gctctctttctttactcac). SSCP analysis has been
described previously.7 Briefly, genomic DNA was extracted from peripheral
blood samples and internally labelled PCR products were generated and
separated on an 8% polyacrylamide/5% glycerol gel. Proband samples are
numbered, M indicates maternal samples, and N indicates normal
controls. In the case of patient 15, the maternal grandmother (GM) and
grandfather (GP) were also analysed. (C) In the father of patient 11,
mosaicism was confirmed by direct sequencing of exon 25 using an ABI
377 automated sequencer. Top panel shows sequence from patient 11
(female heterozygote for 2114G→A, labelled R); middle panel shows
father, presumed mosaic; bottom panel is a normal control.
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does not have haematuria) possesses a very small amount
of the mutated allele (fig 1B), while his maternal
grandmother does not carry the mutation at all. It seems
likely, therefore, that the mutation causing AS in patient 47
arose somatically in his mother, although DNA from the
maternal grandfather (unavailable) would need to be
examined to confirm this.
In patient 11, AS results from the mutation 2114G→A
(G638S) in exon 25 of COL4A5.7 In this case, the proband
was a young female heterozygous for the mutation, who
presented with haematuria at 4 years and in whom a diag-
nosis of AS was supported by a typical renal biopsy,
although no other phenotypic features were observed.
SSCP analysis of DNA taken from her father showed him
to possess roughly equal amounts of the normal and
mutant alleles (data not shown). This result has been con-
firmed with DNA extracted from a second blood sample by
sequencing (fig 1C). It is unlikely that a Klinefelter karyo-
type (XXY) could explain these results, as such people are
sterile; however, somatic mosaicism of XY/XXY cannot be
ruled out. This result is interesting because while patient
11 was diagnosed at an early age, her father surprisingly
showed no signs of AS until he went into renal failure at the
relatively late age of 43. It may be that mosaicism in this
father causes a mild form of AS, since some of the cells in
his kidney may be expressing the normal á5 protein,
resulting in a phenotype more akin to that of a
heterozygous female than that of a hemizygous aVected
male. This is the first report of mosaicism apparently
aVecting the severity of AS.
Overall, this study has uncovered three probable
somatic mosaics out of a total of 77 mutations found. This
number is actually reduced to 3/28 when one includes
only those cases where the parents were examined, giving
a figure of 10.7% mosaic. This number falls into the range
reported for a variety of diseases (0-30%) reviewed by
Zlotogora.9
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